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List of Abbreviations 
AMP, Ampicillin 
AST, Antimicrobial Susceptibility Testing 
ATCC, American Type Culture Collection 
CAZ, Ceftazidime 
CCM, Czech Collection of Micro-organisms 
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CIP, Ciprofloxacin 
CDB, Country Data Bank 
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DTU Food, Technical University of Denmark - National Food Institute 
ESBL, Extended Spectrum Beta-Lactamase 
EQAS, External Quality Assurance System 
ERY, Erythromycin 
EUCAST, European Committee on Antimicrobial Susceptibility Testing 
GEN, Gentamicin 
IATA, International Air Transport Association 
IP. Institute Pasteur 
MIC, Minimum Inhibitory Concentration 
NAL, Nalidixic Acid 
NSSC, National Salmonella and Shigella Center, Thailand  
PHAC, Public Health Agency of Canada  
QC, Quality Control 
SMX, Sulfamethoxazole 
STR, Streptomycin 
SXT, Trimethoprim + Sulphonamides 
TET, Tetracycline 
TMP, Trimethoprim 
WHO, World Health Organization 
WHO GFN, WHO Global Foodborne Infections Network 
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1. Introduction 
Since 2000, ten External Quality Assurance System (EQAS) reports have been issued with this 
report being the 11th. The WHO Global Foodborne Infections Network (WHO GFN)”, focuses on 
enhancing World Health Organisation (WHO) Member States’ capacity to detect and respond to 
foodborne disease outbreaks by conducting laboratory-based surveillance of Salmonella and other 
foodborne pathogens. Since its inception, the scope of WHO GFN has expanded to include 
additional foodborne pathogens like Shigella and Campylobacter. Salmonella, Campylobacter and 
Shigella are among the most important foodborne pathogens worldwide and account for millions of 
cases of diarrheal disease and thousands of deaths per year, impacting both developing and 
industrialized countries. Furthermore, the increased number of Salmonella and Shigella isolates 
which are resistant to antimicrobials is of major concern since these isolates are associated with 
infections characterized by increased morbidity and mortality. 
The EQAS is organized annually by the National Food Institute (DTU Food), Kgs. Lyngby, 
Denmark in collaboration with Centers for Disease Control and Prevention (CDC) in Atlanta, USA; 
World Health Organization (WHO) in Geneva, Switzerland; Public Health Agency of Canada 
(PHAC) in Canada; National Salmonella and Shigella Center (NSSC), National Institute of Health, 
Department of Medical Sciences in Thailand and Institute Pasteur (IP) in Paris, France. The 
technical advisory group for the WHO EQAS program consists of members of the WHO GFN 
Steering Committee.  
Individual laboratory data are confidential and only known by the participating laboratory, the 
EQAS Organizer (DTU Food) and possibly the respective WHO GFN regional centre. All summary 
conclusions are made public. The goal set by WHO GFN aim towards having all national reference 
laboratories perform Salmonella serotyping with a maximum of one deviation out of eight strains 
tested (error rate of 13%) and antimicrobial susceptibility testing (AST) with a maximum error rate 
of 10% (either <5% very major / major errors and <5% minor errors, or <10% minor errors, as 
defined further in this report). 
 
2. Materials and Methods 
2.1 Participants 
A pre-notification announcement of the EQAS 2011 was made through the WHO GFN list server 
on April 22nd, 2011 and a reminder was sent on May 15th, 2011 (App. 1). The pre-notification was 
available in English, Spanish, Portuguese, French, Chinese and Russian, and included invitations to 
participate in the EQAS 2011 program for serotyping and AST of Salmonella and Shigella, 
identification and AST [Minimum Inhibitory Concentration (MIC) determination] of 
Campylobacter, and identification of an unknown foodborne pathogen. Participation was free of 
charge, but each laboratory was expected to cover expenses associated with the analyses performed.  
2.2 Strains 
Eight Salmonella strains, four Shigella strains, and two Campylobacter strains were selected for the 
EQAS 2011 from the DTU Food’s strain collection. The unknown foodborne pathogen, an 
Aeromonas hydrophila strain, was selected by the Laboratory Subcommittee under the WHO GFN 
Steering Committee, and it was provided by PHAC, Canada. Individual sets of Salmonella, 
Shigella, and the unknown strain for identification were inoculated as agar stab cultures in nutrient 
agar. The Campylobacter strains were lyophilized in glass vials by Czech Collection of Micro-
organisms (CCM), Czech Republic. The serotype of each Salmonella strain was determined based 
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on the O (somatic), phase 1 and phase 2 H (flagellar) antigens according to the scheme of 
Kaufmann-White (2007) [1]. The Salmonella serotypes were determined by DTU Food and verified 
by the CDC and IP prior to distribution. The antimicrobial susceptibility patterns of the Salmonella, 
Shigella and Campylobacter strains were determined by DTU Food and verified by CDC. The 
Shigella serotypes were performed by PHAC and verified by the NCCS. A final confirmation after 
production of agar sticks was performed at DTU Food (apart from Shigella serotyping which is not 
routinely performed at DTU Food). 
Laboratories which did not formerly participate in the WHO GFN EQAS AST component were 
provided with lyophilized international reference strains, namely E. coli CCM 3954 ~ ATCC 25922 
and C. jejuni CCM 6214 ~ ATCC 33560, purchased from the Czech Collection of Micro-organisms 
(CCM); The Czech Republic. 
2.3 Antimicrobials 
AST of the Salmonella, Shigella, and Campylobacter strains was performed at the DTU Food, and 
the obtained results were used as a reference standard (App. 2). The following antimicrobials were 
used for AST of Salmonella and Shigella strains: ampicillin, AMP; cefotaxime, CTX; ceftazidime, 
CAZ; ceftriaxone, CRO; chloramphenicol, CHL; ciprofloxacin, CIP; gentamicin, GEN; nalidixic 
acid, NAL; streptomycin, STR; sulfamethoxazole, SMX; tetracycline, TET; trimethoprim, TMP and 
trimethoprim + sulphonamides, SXT. In addition, it was possible to confirm the presence of 
Extended Spectrum Beta-Lactamase (ESBL)-producing strains by using the antimicrobials CTX 
and CAZ in combination with the inhibitor clavulanic acid. The following antimicrobials were used 
for AST of Campylobacter strains: chloramphenicol, CHL; ciprofloxacin, CIP; erythromycin, ERY; 
gentamicin, GEN; nalidixic acid, NAL; and tetracycline, TET. 
MIC determination was performed by using Sensititre systems from Trek diagnostics Ltd, and 
guidelines and breakpoints by Clinical and Laboratory Standards Institute (CLSI) based on 
document M07-A8 (2009) “Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria 
That Grow Aerobically”; Approved Standard - Eighth Edition [2], M100-S21 (2011) “Performance 
Standards for Antimicrobial Susceptibility Testing”; Twenty-First Informational Supplement [3], 
document M31-A3 (2008) “Performance Standards for Antimicrobial Disk and Dilution 
Susceptibility Tests for Bacterial Isolated from Animals”; Approved Standard - Third Edition [4], 
and document M45-A2 (2010) “Methods for Antimicrobial Dilution and Disk Susceptibility Testing 
of Infrequently Isolated or Fastidious Bacteria”; Approved Guideline – Second Edition [5]. 
Guideline were used for interpretation of AST results with the exception of i) ciprofloxacin 
susceptibility testing for which the EUCAST (European Committee on Antimicrobial Susceptibility 
Testing; www.eucast.org) epidemiological cut-off value was utilized; ii) streptomycin susceptibility 
testing for which DTU Food interpretative criteria was utilized; and iii) Campylobacter AST, for 
which EUCAST epidemiological cut-off values were used. For cefotaxime, ceftazidime and 
ceftriaxone values listed in CLSI M100-S21, supplemental Table 2A-S1 were utilized. All 
breakpoints are listed in the protocol (App. 3). 
2.4 Distribution 
Bacterial cultures were enclosed in double pack containers (class UN 6.2) and sent to participating 
laboratories according to the International Air Transport Association (IATA) regulations as 
“Biological Substance category B” classified UN3373. Prior to shipping, laboratories were 
informed about the dispatch date. Import permits were necessary for shipping the parcels to a 
number of countries. Many of the parcels were shipped as “overpack” through international hubs 
which offered to support the costs of further distributing the parcels. Helen Tabor from PHAC; 
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Canada, Matt Mikoleit from CDC; United States, Chaiwat Pulsrikarn from NSSC; Thailand, 
Francois Xavier Weill from IP; France, Rita Tolli from Istituto Zooprofilattico Sperimentale delle 
Regioni Lazio e Toscana, Italy and Rama Murthy from National Institute of Cholera and Enteric 
Diseases, India shipped to all Canadian, American, Thai, Francophone African, Italian and Indian 
institutes, respectively. From China, agreements were in place to send an overpack to Kan Biao 
from Institute for Communicable Disease Prevention and Control, Beijing, however, an import 
permit was not obtained why the Chinese overpack could not be dispatched. Most parcels were 
dispatched in August 2011, and the last in December, 2011. 
2.5 Procedure 
Participants were instructed to download the protocol (App. 3) and additional documents (App. 4a 
and 4b; available only in English) from http://www.antimicrobialresistance.dk/. In addition, they 
were requested to subculture the strains prior to performing the method routinely used in their 
laboratory. The EQAS components included serotyping and AST of eight Salmonella and four 
Shigella strains, identification and MIC determination of two Campylobacter strains, AST of two 
quality control (QC) strains (E. coli CCM3954 / ATCC25922, C. jejuni CCM 6214 / ATCC33560), 
and identification of an unknown foodborne pathogen (Aeromonas hydrophila). Furthermore, the 
laboratories were requested to save and maintain the ATCC reference strains for future proficiency 
tests (App. 4a and 4b). 
After performing the tests, participants were requested to submit i) the obtained results (serogroup 
and / or serotype, MIC values or zone-diameter in millimeters, and antimicrobial susceptibility 
categories of the Salmonella and Shigella strains; ii) identification, MIC values, and antimicrobial 
susceptibility categories of the Campylobacter strains; iii) identification of the unknown strain). The 
results were to be submitted to an electronic record sheet in the WHO GFN web-based database 
through a secured individual login, or alternatively, to send the record sheets from the enclosed 
protocol by fax to DTU Food. The database was activated on September 2nd, 2011 and closed on 
March, 14th, 2012. 
The Salmonella and Shigella strains were categorized as resistant (R), intermediate (I) or 
susceptible (S) to all tested antimicrobials, whereas the Campylobacter strains were categorized as 
resistant (R) or susceptible (S) to all tested antimicrobials. The interpretative criteria followed to 
generate the results used as reference standard were based on both clinical breakpoints and 
epidemiological cut-off values as described above. 
Of note, the authors would like to state that the terms ‘susceptible’, ‘intermediate’ and ‘resistant’ 
should be reserved for classifications made in relation to the therapeutic application of antimicrobial 
agents. When reporting data based on epidemiological cut-off values, bacteria should instead be 
reported as ‘wild-type’ or ‘non-wild-type’ [6]. Due to the different AST methods used by the 
participants and to simplify interpretation of the results, throughout this report we will maintain the 
terms susceptible, intermediate and resistant also when we refer to wild-type and non-wild-type 
strains.  
Susceptibility results had to be interpreted on an individual basis for each antimicrobial tested 
according to the values listed in the protocol (App. 3). Participants were instructed to use the 
Salmonella / Shigella antisera and the antimicrobials used in the methods routinely performed. In 
addition, they were instructed to submit the breakpoints routinely applied in their laboratory for 
categorizing AST results, if different from those listed in the protocol. All laboratories were 
requested to enter MIC values for the C. jejuni (ATCC 33560) reference strain, and either zone 
diameters or MIC values for the E. coli (ATCC 25922) reference strain. After submitting the results, 
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participants were instructed to retrieve an instantly generated report from the secure web site. This 
report was created on an individual basis, and reported all deviations from the expected results and 
suggestions for solving or investigating the cause of error. Deviations of antimicrobial susceptibility 
test results from the expected results were categorized as minor, major or very major. Minor 
deviations are defined as classification of an intermediate strain as susceptible, resistant or vice 
versa (i.e. I ↔ S or I ↔R). Major deviation is the classification of a susceptible strain as resistant 
(i.e. S → R). Very major deviation is the classification of a resistant strain as susceptible (i.e. R → 
S). In this report, the deviations of AST results are divided into two categories, i.e. critical 
deviations which include major and very major deviations, and total deviations which include also 
the minor deviations.  
 
3. Results 
A total of 183 laboratories responded to the pre-notification and were enrolled in the EQAS. When 
the deadline for submitting results was reached, 166 laboratories in 90 countries had uploaded data. 
The following countries provided data for at least one of the EQAS components (Figure 1): 
Albania, Argentina, Australia, Barbados, Belarus, Belgium, Bolivia, Bosnia and Herzegovina, 
Brazil, Brunei Darussalam, Bulgaria, Cambodia, Cameroon, Canada, Central African Republic, 
Chile, Colombia, Democratic Republic of Congo, Costa Rica, Croatia, Cuba, Cyprus, Czech 
Republic, Denmark, Ecuador, Egypt, Estonia, Ethiopia, Finland, France, Gabon, Georgia, Germany, 
Ghana, Greece, Grenada, Guatemala, Honduras, Hungary, India, Iran, Ireland, Israel, Italy, Ivory 
Coast, Jamaica, Japan, Jordan, Kenya, Korea, Lao, Lithuania, Luxembourg, Madagascar, Malaysia, 
Malta, Mauritius, Mexico, Morocco, Nepal, New Zealand, Nicaragua, Nigeria, Sultanate of Oman, 
Palestine, Panama, Paraguay, Peru, Philippines, Poland, Russia, Serbia, Seychelles, Singapore, 
Slovakia, Slovenia, South Africa, Sri Lanka, Sudan, Suriname, Taiwan, Thailand, Tunisia, Turkey, 
United Kingdom, Uruguay, USA, Venezuela, Vietnam, Zambia. It’s noteworthy to mention that due 
to import permit issues, China did not participate in the EQAS 2011; therefore the following part of 
the report does not refer to the strains intended for the 12 registered Chinese participants.  
In the description of results, arbitrary thresholds of quality limits were not used. The results for AST 
are expressed as correct, minor, major, very major, and critical and total deviations as described 
above. 
3.1 Methods used by EQAS participants 
A total of 167 laboratories received Salmonella strains, and 144 (86%) participated in the 
Salmonella serogrouping component of the EQAS, whereas 123 (74 %) participated in the complete 
serotype module of the EQAS. In addition, 127 (76 %) laboratories submitted AST results. Among 
the laboratories performing AST, 111 (87 %) submitted results for the quality control (QC) strain E. 
coli ATCC 25922. The majority (n=88; 79 %) of these laboratories used the disk diffusion method, 
while a MIC determination method was utilized by a smaller number (n=23; 21 %) of laboratories. 
Of 131 laboratories receiving Shigella strains, 109 (83 %) submitted Shigella serogroup results 
(speciation) and 66 (50 %) of these laboratories serogrouping the isolates further analyzed the 
strains to the serotype level. In addition, Shigella AST was performed by 107 (82 %) of these 
laboratories. 
All participating laboratories were through the protocol given information regarding the breakpoints 
used for interpretation when generating the expected interpretation. Expected values were given as 
MIC-values only. In addition, all participating laboratories were instructed on interpretation of 
resistance to third generation cephalosporins and to fluoroquinolones.  
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Of the 123 laboratories receiving Campylobacter strains, 81 (66 %) reported identification results 
and 32 (26 %) submitted AST results for both Campylobacter strains.  
Of the 138 laboratories receiving the unknown culture for identification, 106 (77 %) submitted 
results. 
3.2 Serogrouping and serotyping of Salmonella strains 
In 2011, the percentage of laboratories reporting complete serotype results for all eight strains 
increased to 89% (n=109), thus continuation of the increasing trend observed since 2008. However, 
the number of participants submitting results for all eight isolates did not follow the same trend as it 
decreased by 20 participants from 2010 to 2011. The proportion of correctly serotyped strains 
increased from 89% (n=998) in 2010 to 92% (n=878) in 2011 but faced the same issue with a lower 
number of participants submitting data (Table 1).  
In Table 2, the number of participating laboratories is reported according to the number of correctly 
serotyped samples. In 2011, 82 (67%) of the 123 participating laboratories serotyped all eight 
strains correctly, and 17 (14%) laboratories correctly serotyped seven of the eight strains. In 
summary, in 2011, a total of 99 (81%) participating laboratories met the threshold for adequate 
performance of Salmonella serotyping, which represents a considerable increase compared to 2010 
where 107 (72%) of the participating laboratories met the performance quality threshold. In 
addition, 91% of the participating laboratories correctly identified half of the strains, which 
represents a 5% increase compared to 2010 (86%). Furthermore in 2011, all participants had at least 
one isolate correctly serotyped which was last observed four years ago. 
In Table 3, the performance of Salmonella serotyping is reported on a region-based categorization 
of participating laboratories. Overall, the accuracy of serotyping again this year increased in most 
regions compared to 2010. One region, Latin America, experienced an influx of EQAS participants 
in 2011. The other regions experienced either a slight decrease from one to three participants in 
2011 or had a constant level of participants. In 2011, the Chinese region could unfortunately not 
participate due to import permit issues.  
The number of tested strains decreased in most in regions with exception in Central Asia & Middle 
East, Latin America, and Southeast Asia. The accuracy of serotyping was constant or increased in 
most in laboratories compared to 2010. The most profound increases were observed in Africa, 
Central Asia & Middle East, and Southeast Asia. A decrease in accuracy of serotyping was only 
observed in Caribbean and North America compared with 2010.  
The overall performance of laboratories performing Salmonella serogrouping was excellent 
compared to 2010 with seven of the isolates having af deviation level below 5% and ranging from 
0.7% (WHO S11.4; Derby) to 5.8% (WHO S11.2; Westhampton) (Table 4). 
Of 130 laboratories performing serotyping of the internal quality control strain (WHO S11.7, used 
in EQAS 2000, 2001, 2004, 2006, 2007, 2008, 2009, and 2010), 128 (98%) reported a correct 
result, thus leading to a deviation rate of only 2% (Table 4). Thus in 2011, the ability of 
participating laboratories to correctly serotype the internal quality control strain was again the 
highest ever recorded from the beginning of the WHO EQAS (Table 5). A deviation of only 2% (to 
be precise, 1.5%) is an outstanding result. 
Deviations in Salmonella serotyping ranged from 1.5% (WHO S11.7) to 14.4% (WHO S11.4) 
(Table 4). In 2011, all but one of the isolates (WHO S11.4 Derby, 14.4%; WHO S11.8 Berta 
10.1%) exhibited deviation levels above the magic number of 10% (Table 4).  
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3.3 Antimicrobial susceptibility testing (AST) of Salmonella strains 
A total of 11,353 antimicrobial susceptibility tests were performed in 2011 by 127 participating 
laboratories (Table 8). Of the submitted results, 91% were in agreement with the expected result, 
which is a slight reduction compared to 2010 – the second year in a row where a decrease have been 
observed (Table 6). Minor, major and very major deviations were observed in 4%, 2% and 3% of 
the submitted results, respectively (Table 6). 
Some difficulties in assessing antimicrobial susceptibility were encountered for the tested 
combinations of strains and antimicrobials. The difficulties were mainly in assessing susceptibility 
to the usual antimicrobial suspects; STR and CIP, and especially showed for the isolates WHO 
S11.4 Derby and WHO S11.6 Onireke (Table 7).  
Major deviations categorized by tested antimicrobial are reported in Table 8. Notably, a large 
number of critical deviations were observed for CIP (20%). This antimicrobial together with STR, 
NAL, and TET also resulted in very high numbers of total deviations (Table 8). In 2011, we 
maintained the average number of overall critical and total deviations with 5% and 9%, 
respectively.  
In 2011, the number of laboratories participating in the AST component of EQAS decreased in all 
regions with exception of Southeast Asia (Table 9). Unfortunately, the largest decrease were 
observed in regions consisting mainly of developing countries needing guidance, such as in Africa, 
decreasing with five laboratories (23% reduction compared to 2010), Central Asia & Middle East 
decreasing with three laboratories (42% reduction compared to 2010), and Caribbean decreasing 
with two laboratories (50% reduction compared to 2010). Overall, the performance of AST differed 
in all regions, most notably in the African and Caribbean regions where the performance (percent 
correctly tested) increased from 84.7% in 2010 to 87.0% in Africa and from 90.9% in 2010 to 
96.5% in 2011. Overall, 87.0% (Africa) of the antimicrobial susceptibility test results to 96.5% 
(Caribbean) were reported correctly (Table 9).  
Antimicrobial susceptibility to E. coli ATCC 25922 was tested by 23 laboratories with the MIC 
determination method and by 88 laboratories with the disk diffusion method. The proportion of 
laboratories which submitted values outside the acceptable interval for the reference strain E. coli 
ATCC 25922 is reported in Table 10. The percentages of laboratories which reported MIC values 
outside the intervals accepted for the QC strain ranged from 0% (CHL, CTX, NAL, and TMP) to 
9% (CIP and GEN) (Table 10). These results indicate that there is no consistency with what caused 
problems in 2011. In general, laboratories using the MIC determination method reported values 
within the acceptable interval in higher percentages compared to the laboratories using the disk 
diffusion method, with the exception to CAZ, CIP, and STR testing (Table 10).  
3.4 Serogrouping and serotyping of Shigella strains 
Like in 2010, the performance of Shigella speciation was highly satisfactory in 2011, as the 
percentages of deviations were very low for all the four test strains, ranging from 0.9% (WHO SH 
11.4) to 2.8% (WHO SH 11.1 and WHO SH 11.2) (Table 11). The deviations observed among 
laboratories performing full serotyping were satifactory ranging from 5.7 % (WHO SH 11.1) to 
11.7% (WHO SH 11.4). The strain resulting in most deviations was WHO SH 11.4: Shigella 
flexneri serotype 1b, reported as serotype 1a and 3a by six and one participating laboratories, 
respectively.  
In Table 12, the performance of Shigella serotyping is reported according to geographical 
distribution of participating laboratories. The majority of participating laboratories was located in 
Latin America (n=15), Southeast Asia (n=13), and Europe (n=16). The number of participating 
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laboratory decreased in most regions compared to 2010 with exception of Europe and Latin 
America. The accuracy of Shigella serotyping results were in many regions excellent ranging from 
84.8% (Southeast Asia) to 100% (Africa, Central Asia and Middle East, Oceanic, and North 
America). Unfortunately, the Caribbean countries did not participate in the Shigella component. 
3.5 Antimicrobial susceptibility testing (AST) of Shigella strains 
A total of 4,184 antimicrobial susceptibility tests were performed in 2011 by 107 participating 
laboratories. Agreement with the expected result was achieved in 92% of the reported results, which 
is still a reduction compared to 2009 (Table 13). Minor, major and very major deviations were 
observed in 2%, 1% and 4% of reported results, respectively (Table 13). 
Difficulties in assessing antimicrobial susceptibility to CIP and CAZ was encountered as resistance 
in isolate WHO SH-11.4 (Table 14). CAZ, CIP, NAL, and STR accounted for 12.0%, 40.7%, 
11.0% and 10.5% of total deviations, respectively (Table 15).  
Two ESBL-producing Shigella strains were included in the EQAS 2011 trial. The participating 
laboratories had between 2.0% and 12.0% deviating results for CAZ, CRO, and CTX (Table 15). 
In 2011, all participating regions partook in the Shigella AST component. The majority of 
participating laboratories was located in the European, Latin American, Southeast Asian and 
African regions where 24, 20, 19 and 16 laboratories participated to this EQAS iteration, 
respectively (Table 16). By considering participating laboratories in relation to their geographical 
location, the percentage of correct AST results ranged from 86.0% (Africa) to 97.7% (Caribbean). 
The African, North American, and Southeast Asian regions reported results presenting the highest 
percentages of critical and total deviations, i.e. 11.9%, 9.2%, and 6.9% critical deviations, and 
13.7%, 9.2%, and 9.0% total deviations, respectively (Table 16). 
3.6 ESBL-producing Salmonella and Shigella 
An optional part of the EQAS was to detect and confirm Extended-Spectrum Beta-Lactamase 
(ESBL) production. If participating in this item of the EQAS, all strains showing reduced 
susceptibility to cefotaxime (CTX), ceftazidime (CAZ) and/or ceftriaxone (CRO) should be tested 
for ESBL production. 
One of the Salmonella (WHO S-11.5), and two of the Shigella (WHO SH-11.2 and WHO SH-11.4) 
test strains were ESBL-producing. The WHO S-11.5 (Salmonella Havana) harboured the blaCTX-M-
15 gene whereas WHO SH-11.2 Shigella sonnei and WHO SH-11.4 Shigella flexneri serotype 1b 
harboured the blaCMY-2 and blaCTX-M-15 gene, respectively. Uploaded results regarding ESBL-
producing strains are listed in Table 17 presenting the fact that up to 8% of the uploaded results for 
the confirmatory testing were deviating. 
3.7 Identification of Campylobacter strains 
Participation in the EQAS 2011 Campylobacter component was requested by 122 laboratories 
(disregarding China), of which 81 (66%) submitted results within the deadline. Of the participating 
laboratories, 59% and 70% performed correct species identification for strain #1 (C. coli) and #2 (C. 
coli), respectively (Table 18). A considerable large number of laboratories; 19 and 17 reported #1 
and #2 being C. jejuni. 
In Table 19, the performance of Campylobacter identification is reported according to geographical 
location of participating laboratories. The majority (n=25; 31%) of participating laboratories were 
as in 2009 and 2010 located in Europe, but a large number of participates were also observed Latin 
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America (n = 19). The accuracy in Campylobacter identification ranged from 0% (Caribbean) to 
100% (Oceanic region). In 2011, the performance dropped tremendously compared to 2010 in 
regions with exception of Oceania.  
3.8 MIC determination of Campylobacter strains 
A total of 387 MIC determinations were performed in 2011 by 32 participating laboratories (Table 
22). Among the reported results 93.8% were in agreement with the expected result (Table 20). 
Major and very major deviations were observed in 2.8% and 3.4% of reported results (Table 20). 
WHO C-11.2 created a few difficulties in assessing antimicrobial susceptibility for STR and TET 
(Table 21). This was likewise displayed in the overall performance by antimicrobial where 13.3% 
and 8.3% deviations were reported for STR and TET, respectively (Table 22).  
In 2011, MIC values were submitted by almost all laboratories with exception of Caribbean (Table 
23). An increase in participation was observed in Africa going from two laboratories to six. 
Agreement with expected values was observed in percentages ranging from 75.0% (Central Asia 
and Middle East) to 100% (Europe, North America, Oceania, and Russia) (Table 23). The highest 
percentages of critical deviations were reported from laboratories in Africa, Central Asia and 
Middle East, and Southeast Asian regions 17.3%, 25.0, and 15.0%, respectively (Table 23).  
MIC values of reference strain C. jejuni ATCC 33560 were tested by 26 laboratories. Of these, 17 
laboratories used micro-dilution procedures, while nine laboratories used agar-dilution procedures 
and tested only CIP, ERY and GEN. Overall, the percentage of laboratories which submitted values 
within the acceptable interval for the reference strain seemed to experience most problems with CIP 
and ERY, which showed 77% and 75% results within range, respectively. (Table 24).  
3.9 Identification of the unknown culture 
Identification of the unknown enteric pathogen (Aeromonas hydrophila) was performed by 106 
laboratories (Table 25). Overall, 83% of the participating laboratories identified the strain as 
Aeromonas hydrophila. 
 
4. Discussion 
4.1 Serogrouping and serotyping of Salmonella strains 
As in previous years, the selection of serovars included in the 2011 WHO GFN EQAS trial was 
based both on the 15 most common serovars submitted to the WHO GFN Country Data Bank 
(CDB) [7] and on various reports and scientific publications. To facilitate the global assessment of 
Salmonella serotyping capacity, we chose serovars which may be very common in certain regions 
and sporadically encountered in other regions. In 2011, we included Salmonella Enteritidis as in 
previous years as it serves as internal control but also as it is one of the most frequent serovars 
worldwide despite a decreasing trend. Salmonella Derby; a pig related serovar seems to be quite 
frequent in Europe ranking high on the top 20 list whereas it appears to be less frequent in Southeast 
Asia and South Americas, however, still among top 20. In the other regions, Salmonella Derby is 
not listed among top 20 causing human illness [7]. Another relatively frequent serovar; Salmonella 
Muenchen was included the EQAS 2011. This serovar is moderately common in North America 
and South America and ranked low in the top 20 in Europe. In 2011 EQAS, a number of less 
common to rare serovars were included such as Salmonella Abaetetuba and Salmonella Onireke. 
Salmonella Abaetetuba has been described causing infections in sea lizards from the Galapagos 
Islands [8] whereas Salmonella Onireke has been isolated from chicken from Nigeria. It has been 
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speculated that this serovar might originate from the environment and reptiles [9]. Salmonella Haifa 
has been reported in several cases associated with poultry in Africa e.g. Ethiopia and Nigeria [9] but 
also causing diarrhea in humans including travelers. The serovar also seems to be a rare encounter. 
Another poultry related serovar; Salmonella Havana was included the panel of EQAS isolates. This 
serovar seems not to be frequent but there is evidence of it being found in multiple reservoirs 
including camels, pigs, raptors, birds, and including infection in humans [10]. Lastly, Salmonella 
Westhampton was included the EQAS panel. This serovar is as most of this year’s panel 
infrequently found around the world. Overall, the panel of 2011 was greatly influenced by rare or 
infrequently observed serovars hopefully making the participants curious of their nature. 
The number of laboratories which serotyped all eight Salmonella strains increased once again to 
89% (n = 109) in 2011, which represents the best results since 2000 where 92% of the participants 
tried to serotype all of the eight serovars. However in 2000, only 34 participants serotyped all eight 
isolates. We also observed a minor increase in performance compared to 2011. This might be due to 
the lower number of participants in this year’s EQAS lacking the countries performing less well. 
This seems to be the case in all test in this year’s EQAS. It is of course nice to see a positive 
increase in performance but at the same time unfortunate to observed that developing countries 
might ignore the EQAS invitation due to previous years’ poor results. One of the purposes of the 
EQAS is also to identify areas where training is needed or resources are poor.  
Similar to the result of participants attempting to serotype all isolates, the percentage of correctly 
serotyped strains also increased to the best result ever recorded. This also indicates the hypothesis 
indicated above. However, it is still an excellent achievement to have 92% (n=109) of the 
participants correctly serotype the eight Salmonella isolates.  
The isolates included in this year’s EQAS are not believed to be easier to type compared to the last 
couple of years as we in 2011 have four isolates containing the G complex which often is a 
challenge due to the many different antisera needed to pin out the correct antigens. Furthermore, 
two isolates were of a less common somatic antigen e.g. O:11 and O:13. Similarly, one isolate 
contained a z10 H-antigen – all contributing to a moderate level of difficulty. 
An astonishing 98% of participating laboratories correctly serotyped the internal control strain this 
year, and thereby even exceeded the 97% from the 2010-iteration. This is again the highest 
percentage recorded since the beginning of the EQAS. The quality threshold of correctly serotyping 
at least seven strains was met by 81% of participating laboratories, thus demonstrating once again 
an excellent improvement compared to previous years.  
In general, the obtained results indicate that most laboratories worldwide have the capacity to 
serotype the most common Salmonella serovars. It is noteworthy that many developing regions 
obtained better results compared to 2010 which is truly an impressive accomplishment. However, a 
small reduction of participants was also observed from specifically those regions lacking potentially 
poor performers. 
In 2011, main problem in serotyping the isolates are the same as in previous years with exception of 
2010. The problem is linked to difficulties in the characterization of flagellar antigens. In 2011, 
especially the Complex G played a significant role in the number of incorrect identification of the 
serotypes. This most likely is a consequence of a lack of good quality antisera, financial resources, 
and availability. However, we believe this problem will be diminished with time due to the 
advancing of new sequence-based molecular techniques and the decreasing price of those methods. 
In the future, we foresee that multi locus sequence typing (MLST) and whole genome sequencing 
will replace conventional microbiological techniques such as serotyping and identification of 
resistance genes, plasmids, virulence genes etc. [11, 12]  
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4.2 Antimicrobial susceptibility testing (AST) of Salmonella strains 
Overall, 91% of the Salmonella AST was correctly performed, and critical deviations were 5%. 
This result is still satisfactory but is still a decrease in performance since 2009. Noteably, the 
number of participating laboratories in the antimicrobial susceptibility testing component has now 
decreased since in 2008 from 168 to 127 in 2011. This is a highly worrisome development as the 
level of antimicrobial resistance is increasing with a tendency of creating more multi drug resistance 
pathogens. We need to strengthen the awareness about antimicrobial resistance and the need for 
performing antimicrobial susceptibility testing accurately. 
In 2011, we followed the guidelines for MIC breakpoint interpretation as well as the expert 
guidelines on the interpretation of cephalosporin resistance which was distributed in 2010. 
Similarly, participating laboratories were asked to utilize EUCAST epidemiologic cut off values for 
interpretation of CIP susceptibility. The EQAS organizers utilized the lower epidemiologic cut off 
value for ciprofloxacin to facilitate the detection of low-level resistance which may be caused either 
by alteration of the drug target due to a single point mutation in the gyrase-encoding gene or by 
protection of the drug target due to qnr proteins which are encoded by plasmid-mediated genes. Of 
note, low-level ciprofloxacin-resistant strains (extra-intestinal non-typhoid Salmonella and S. 
Typhi) would be interpreted as intermediate according to the newly issued CLSI clinical 
breakpoints. However, this will not determine plain non-typhoid Salmonella or extra-intestinal non-
typhoid Salmonella and S. Typhi as resistant toward fluoroquinolones even by using the new CLSI 
guidelines of 2012 why we maintain the EUCAST guidelines for interpretation of these compounds. 
As in previous years, a high percentage of total deviations was observed for CIP, STR, and TET 
susceptibility tests. Interestingly, SMX susceptibility tests seemed not to create that many 
deviations in 2011 compared to previous years. In contrast, CIP and NAL seemed to cause some 
challenges in 2011 which was linked to detection of qnr genes in isolate WHO S-11.4 and WHO S-
11.6 where participants indicated those isolates incorrectly as intermediate or resistant for NAL and 
the opposite for CIP. In the case of STR susceptibility test, the difficulties in testing this compound 
appear to be continuous. In Europe, discussions have been raised about the value of keeping this 
drug in the panel of antimicrobials ideal for monitoring. Publications suggesting new and updated 
cut off values for STR have also shown an overlapping distribution between the wild-type and non-
wild-type complicating the exact determination of the resistant population [13].  
In the case of SMX susceptibility test, we observed a decrease in deviating results in 2011 
compared to those of EQAS 2010. A pit fall as regards reading the result of this antimicrobial is 
caused by the fact that it is bacteriostatic meaning that the zone diameter or the MIC should be read 
at 80% reduction of growth. A common mistake for this antimicrobial is therefore to register false 
resistance. This year, four of the test strains were resistant to SMX compared to two in 2010 which 
might explain the decrease in deviating results. 
In general, data from the Salmonella AST component of EQAS 2011 demonstrate a minor reduction 
in the performance compared to 2009 and 2010. Of note, laboratories in Africa and Caribbean 
performed better compared to 2010 whereas Central Asia and Middle East, North America, Russia, 
and Southeast Asia obtained less correct test results compared to 2010.  
When performing AST, the inclusion of reference strains for internal QC is extremely important. If 
correctly used, the reference strain will provide QC for both the method and the reagents. 
Unfortunately, only 111 (87%) participating laboratories submitted AST results of the QC strain. 
Thus a better result compared to 2010. We always encourage laboratories to conduct quality 
assurance when performing AST. To facilitate the internal QC, we provide each new participating 
laboratory with the reference strain E. coli ATCC 25922. Laboratories participating in EQAS are 
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invited to retain and maintain the QC strain for future use. As a rule, results for the test organisms 
should not be reported if ≥ 3 out of 30 results for the QC strain are outside the expected interval. In 
2011, we observed an improvement in AST of QC strains using MIC determination compared to 
2010 where the range of participants reporting results outside of the QC range were between 10% to 
36% for CHL, CTX, NAL, TMP in contrast to no deviations in 2011. Compared to disk diffusion, 
similar or worse results were obtained in 2011 as to data outside the QC ranges. These erroneous 
disk diffusion results typically arise from inadequate standardization of methodologies, lack of good 
quality culture media and improper storage of antimicrobial-containing disks. Thus, deviations in 
AST results can likely be corrected by improving QC practices.  
4.3 Serogrouping and serotyping of Shigella strains 
In EQAS 2011, 104 to 109 correctly identified the four Shigella isolates resulting in a deviation 
range of 0.9% to 2.8% showing a high capacity within Shigella diagnostics.  
Only half (48%-66%) of the participants conducting correct identification carried on and performed 
the serotyping. For WHO SH-11.4 (S. flexneri serotype 1b) causing most deviations in serotyping, 
six participants failed to detect the right serotype among antigen 1.  
Most regions encountered a drop in participation where only participation increased in Europe and 
Latin America. However, in several regions no serotyping errors was recorded e.g. Africa, Central 
Asia and Middle East, North America and Oceania indicating the same hypothesis as for the 
Salmonella component that the developing countries are lacking in 2011 which in previous years 
obtained poor results.  
4.4 Antimicrobial susceptibility testing (AST) of Shigella strains 
In EQAS 2011, AST of Shigella spp. was performed by 107 laboratories which is a slight increase 
compared to 2009 and 2010. A total of 92% of the participants obtained a correct AST results which 
is within the same level as for AST in Salmonella. In comparison with the Salmonella results, a few 
more deviations categorized as minor were observed in contrast to fewer major and very major 
deviations. Overall, the AST results of the Shigella component were equal to what was seen in 
2010. One could speculate if some laboratories participate in either the Shigella or the Salmonella 
AST component as the reason why the level of participation appear to have been declining over the 
years.  
The results show that especially isolate WHO SH-11.4 caused some problems susceptibility testing 
towards CAZ, CHL, CIP, and NAL. In general, a large proportion of deviations testing CIP and 
CAZ were observed associated with isolates WHO SH-11.2 and WHO SH-11.4 that also were 
ESBL producers. 
Accordingly, we observed high percentages of deviations related to CAZ, CIP, NAL, and 
susceptibility test results. The reason why some laboratories obtain deviations when testing CAZ 
might be the weakness of the antimicrobial for testing e.g. blaCTX genes and ampC’s which both 
isolates harboured. The high number of deviations to CIP and NAL were the same as for 
Salmonella. Surprisingly, participating laboratories performed SMX and TET susceptibility testing 
of Shigella more correctly than in Salmonella. This has also been observed in other EQAS towards 
E. coli conducted in Europe. Apparently, E. coli and Shigella do not present the same challenges 
with those compounds as Salmonella. 
All regions submitted results with an overall regional performance similar to the one described for 
Salmonella AST differing with a maximum of 5%.  
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4.5 ESBL-producing Salmonella and Shigella 
An emerging problem worldwide is ESBL-producing gram-negative bacteria. Three test strains, one 
Salmonella (WHO S-11.5) and two Shigella, (WHO SH-11.2 and WHO SH-11.4) were ESBL-
producers and therefore relevant for the component of the EQAS including detection and 
confirmation of this phenotype. 
The WHO S-11.5 (Salmonella Havana), WHO SH-11.2 Shigella sonnei and WHO SH-11.4 
Shigella flexneri serotype 1b harboured blaCTX-M-15, blaCMY-2 and blaCTX-M-15 genes, respectively. 
Some of the genes, e.g. blaCTX genes and ampC’s may not confer resistance to all cephalosporins, 
for example, CAZ appears to be an antimicrobial that does not always detect ESBL-producers. In 
general, it is recommended that more than one cephalosporin is used for the detection of an ESBL-
producing Salmonella when initially screening the isolate. The cephalosporins cefotaxime, 
cefpodoxime, ceftiofur, ceftriaxone, and ceftazidime were all found useful in detecting isolates with 
ESBL or plasmidic ampC by Aarestrup et. al. [14], however, cefotaxime, cefpodoxime, and 
ceftriaxone were superior to the other two. 
4.6 Identification of Campylobacter strains  
In 2011, we selected only Campylobacter coli strains. Interestingly, since 2003 where this 
component was implemented the WHO EQAS, we have never observed correct identification of C. 
coli exceeding 85% (2010). In contrast, correct identification of Campylobacter jejuni seems to be 
easier as both 92% and 95% of correct identification of C. jejuni were obtained in 2010 and 2009, 
respectively. One of the explanations may be that when conducting a conventional hippurate 
hydrolysis test, that some C. coli are incorrectly identified based on false positive hippurate 
hydrolysis test results. The weakness of the conventional hippurate hydrolysis test is that sometimes 
the test suspensions develop a weak bluish color when testing C. coli that for the untrained person 
often will be mistaken as being positive indicating C. jejuni. We noticed a huge difference in 
performance per region in the different years. The regions performing less satisfactory one year 
performed well the following year. However, this may be the result of the panel containing either C. 
jejuni or C. coli. Overall, the results related to Campylobacter identification were poor compared to 
2010.  
4.7 Antimicrobial susceptibility testing (AST) of Campylobacter strains 
In EQAS 2011, 32 laboratories participated in the MIC determination and performed overall 
satisfactorily, since they obtained 93.8% correct test results. In contrast to 2010, only minor 
problems testing the antimicrobials were observed. WHO C-11.2 created some minor problems 
when mainly testing STR and TET resulting in 13.3% and 8.3% critical deviations. There is no 
obvious explanation to these deviations. In 2011, laboratories from the Central Asia & Middle East 
and the Oceanic regions participated in this EQAS component. In contrast, the Caribbean did not 
participate.  
In 2011, 26 (81%) participating laboratories submitted AST results for the QC strain. The majority 
of deviations were observed for CIP and TET susceptibility testing by micro-dilution at 42 °C and 
GEN susceptibility testing by micro-dilution at 37 °C. Interestingly, we noticed the same deviations 
as for 2010. Some problems were observed towards testing ERY when agar dilution at 42 °C was 
used, and hardly any when agar dilution at 37 °C was used. In general, AST of the QC strain was 
satisfactory.  
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4.8 Identification of the unknown culture 
In EQAS 2011, we included an Aeromonas hydrophila strain to see how effectively the participants 
can differentiate Aeromonas from Vibrio spp. Of 106 laboratories delivering results, 88 (83%) 
identified the strain correctly. Only five participants indicated the unknown isolate as being a Vibrio 
spp. This indicates that most laboratories in fact are able to distinguish between Vibrio and 
Aeromonas.  
 
5. Conclusions  
The acceptance threshold for the Salmonella serotyping EQAS component was met by 81% (n=99) 
of the participating laboratories. In addition, 89% of the laboratories tested all eight strains and a 
total of 92% of all tests were correct, thus representing an increase compared to 2010. Additionally, 
the ability in correctly testing the internal QC strain increased from 97% in 2010 to 98% this year.  
This year, the obtained results indicate that most laboratories worldwide have the capacity to 
serotype the most common Salmonella serovars. It is noteworthy that many developing regions 
obtained better results compared to 2010 which is truly an impressive accomplishment. However, a 
small reduction of participants was also observed from specifically those regions lacking potentially 
poor performers.  
The main problem as regards serotyping appears to have been linked to difficulties in the 
characterization of flagellar antigens. In 2011, this especially concerns the Complex G and is most 
likely a consequence of a lack of good quality antisera, financial resources, and availability. In the 
future, however, it is likely that sequence-based molecular techniques will be competitive with 
traditional typing methods. 
Concerning the Salmonella AST component, it is important to stress the importance of harmonizing 
the methodology and having adequate guidelines available. The EQAS 2011 results as regards AST 
of Salmonella showed a slight decrease of performance. Overall, the acceptance threshold was met, 
and we identified 4% minor and 5% critical deviations. CIP, NAL, STR and TET caused the 
majority of the observed deviations. Compared to 2010, laboratories in Africa and Caribbean 
performed better, whereas Central Asia and Middle East, North America, Russia, and Southeast 
Asia obtained less correct test results.  
Strengthened awareness of the importance of performing internal quality control is crucial and is 
introduced in many of the participating laboratories. Sixteen (13%) participating laboratories did 
not report data for AST of the QC strain, though, despite the EQAS organizers repeated 
recommendation of the use of such QC strains and the provision of certified strains to new 
participants. The component related to AST of the QC strain was in general less satisfactory than in 
previous years. It is important to emphasize that this component represents the true indicator of the 
quality of AST performance.  
For the Shigella component in EQAS 2011, consisting of of serogrouping, serotyping and AST, 
most laboratories correctly serogrouped the four Shigella strains, and a maximum of 2.8% 
deviations was observed. A total of 65 laboratories performed serotyping. Only minor regional 
differences were observed, and the highest number of deviations was reported from laboratories 
from the South East Asian region. 
The results obtained in the Shigella AST component suggest conclusions similar to the ones 
reported above concerning the Salmonella AST. 
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Detection and confirm Extended-Spectrum Beta-Lactamase (ESBL) production has been included 
as an optional part of this EQAS due to the emerging importance of the phenotype in gram-negative 
bacteria. One of the Salmonella (WHO S-11.5), and two of the Shigella (WHO SH-11.2 and WHO 
SH-11.4) test strains were ESBL-producing. The obtained results indicate that there is still room for 
improvement in this context. 
A total of 123 laboratories received Campylobacter for identification, but only 81 laboratories 
uploaded data. Both strains were C. coli and the difficulties in identifying these (59% and 70% 
correct results for the two strains) might be caused by issues with the hippurate analysis. The 
majority of difficulties in Campylobacter identification were experienced by laboratories in the 
regions of Africa, Central Asia & Middle East, the Caribbean, Russia and Latin America.  
EQAS 2011, a total of 32 laboratories participated in MIC determination of Campylobacter. The 
acceptance threshold used for Salmonella was applied and was almost met, since we observed 6.2% 
critical deviations overall, and the data on antimicrobial level revealed that NAL, STR and TET 
susceptibility testing were the most challenging. Of the 32 participating laboratories, 26 performed 
AST of the QC strain. For this strain, the highest level of results outside the QC-range were seen for 
CIP and ERY. 
The unknown strain, Aeromonas hydrophila, was selected to see how effectively the participants 
could differentiate between Aeromonas from Vibrio spp. Overall, 83% of the participating 
laboratories identified the strain correctly and thereby indicates that most laboratories are able to 
distinguish between Vibrio and Aeromonas.  
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Figure and Tables 
 
Figure 1. Countries participating* in the WHO EQAS 2011 
 
*marked in green.  
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Table 1. EQAS participating laboratories’ performance of Salmonella serotyping  
 
EQAS 
iteration 
 
Labs serotyping all 
provided strains Correct test results 
No. % No. % 
2000 34 92 165 76 
2001 79 82 513 72 
2002 80 81 668 91 
2003 69 54 692 80 
2004 78 61 701 81 
2006 105 81 808 85 
2007 109 78 920 88 
2008 100 66 888 83 
2009 119 83 974 86 
2010 129 87 998 89 
2011 109 89 878 92 
Average 92 76 746 85 
 
Table 2. Ability of EQAS participating laboratories to serotype the test Salmonella strains  
 
Number 
of strains 
correctly 
serotyped 
Participating laboratories 
EQAS 
2000 
EQAS 
2001 
EQAS 
2002 
EQAS 
2003 
EQAS 
2004 
EQAS 
2006 
No. % No. % No. % No. % No. % No. % 
8 9 24 34 35 52 53 32 25 41 32 42 32 
7 9 24 13 14 19 19 15 12 14 11 35 27 
6 4 11 9 9 12 12 18 14 16 13 19 15 
5 3 8 9 9 4 4 23 18 16 13 12 9 
4 3 8 4 4 1 1 14 11 11 9 7 5 
3 4 11 8 8 4 4 13 10 10 8 5 4 
2 2 5 3 3 5 5 4 3 10 8 3 2 
1 2 5 5 5 1 1 5 4 5 4 4 3 
0 1 3 11 11 1 1 3 2 4 3 3 2 
In total 37 100 96 100 99 100 127 100 127 100 130 100 
Number 
of strains 
correctly 
serotyped 
Participating laboratories 
EQAS 
2007 
EQAS 
2008 
EQAS 
2009 
EQAS 
2010 
EQAS 
2011 
AVERAGE 
EQAS 
2000 - 2011 
No. % No. % No. % No. % No. % No. % 
8 66 47 50 33 76 50 91 61 82 67 52 43 
7 29 21 36 24 29 19 16 11 17 14 21 17 
6 13 9 11 7 7 5 12 8 10 8 12 10 
5 11 8 14 9 13 8 9 6 2 2 11 9 
4 7 5 12 8 5 3 6 5 4 3 7 6 
3 6 4 9 6 7 5 2 1 4 3 7 5 
2 2 1 8 6 5 3 2 1 1 1 4 3 
1 6 4 9 6 6 4 7 5 3 2 5 4 
0 0 0 2 1 5 3 3 2 0 0 3 2 
In total 140 100 151 100 153 100 148 100 123 100 121 100 
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Table 3. Region-based categorization of EQAS participants’ performance of Salmonella serotyping 
 
Region EQAS iteration 
No. of 
labs 
No. of 
strains 
serotyped  
% strains 
correctly 
serotyped 
Countries participating 
in EQAS 2011 
Africa 
2001 6 37 73.0 
Cameroon, Central African 
Republic, Congo, Rep. of, Ivory 
Coast, Madagascar, Mauritius, 
Morocco (2), South Africa,  
Tunisia 
2002 9 62 87.1 
2003 11 70 71.4 
2004 9 51 62.7 
2006 16 95 71.6 
2007 11 73 80.8 
2008 10 71 49.3 
2009 15 94 75.5 
2010 13 83 67.5 
2011 10 57 79.2 
Central Asia & 
Middle East  
2001 10 60 50.0 
Israel, Jordan, Oman 
2002 5 30 83.3 
2003 5 35 54.3 
2004 5 33 54.5 
2006 5 35 74.3 
2007 5 40 55.0 
2008 5 34 61.8 
2009 5 32 46.9 
2010 5 22 75.9 
2011 3 23 95.8 
      
Caribbean 
2001 0 0 0 
Barbados 
2002 0 0 0 
2003 3 18 61.1 
2004 2 8 87.5 
2006 3 14 78.6 
2007 2 9 77.8 
2008 3 14 78.6 
2009 3 12 83.3 
2010 2 13 92.9 
2011 1 7 87.5 
Europe  
2001 43 323 80.5 
Albania, Belgium, Bosnia and 
Herzegovina (2), Bulgaria (2), 
Croatia, Cyprus, Czech Republic, 
Denmark (2), Estonia, Finland, 
France, Germany, Greece (2), 
Hungary, Ireland, Italy (12),  
Lithuania, Luxembourg, Malta, 
Poland (3), Serbia, Slovakia, 
Slovenia, Turkey, United Kingdom 
2002 50 384 90.0 
2003 60 401 84.8 
2004 57 392 84.7 
2006 52 403 86.4 
2007 54 415 89.4 
2008 50 379 82.3 
2009 47 362 93.1 
2010 45 332 94.1 
2011 42 314 94.6 
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Table 3 (continued).  
Region-based categorization of EQAS participants’ performance of Salmonella serotyping 
 
Region EQAS iteration 
No. of 
labs 
No. of 
strains 
serotyped  
% strains 
correctly 
serotyped 
Countries participating 
 in EQAS 2011 
North America  
2001 4 32 87.5 
Canada, United States of America 
2002 2 16 100.0 
2003 6 41 95.1 
2004 8 55 81.8 
2006 10 80 96.3 
2007 12 94 97.9 
2008 11 84 95.2 
2009 12 90 92.2 
2010 13 103 100.0 
2011 11 81 97.6 
      
Oceania  
2001 4 30 100.0 
Australia,New Zealand 
2002 6 43 93.0 
2003 6 46 93.5 
2004 5 38 97.4 
2006 5 37 94.6 
2007 4 32 100.0 
2008 4 30 93.3 
2009 4 32 96.9 
2010 4 32 100.0 
2011 4 32 100.0 
Russia  
2001 1 8 12.5 
Belarus, Georgia, Russia 
2002 1 8 62.5 
2003 1 7 14.3 
2004 4 26 69.2 
2006 5 40 80.0 
2007 8 51 80.4 
2008 6 40 90.0 
2009 7 49 91.8 
2010 8 54 87.1 
2011 7 48 87.3 
      
Latin America  
2001 11 78 57.7 
Cuba (2), Argentina (2), Brazil (2), 
Chile, Colombia (3), Costa Rica (2), 
Ecuador (2), Guatemala, Honduras, 
Nicaragua, Panama, Paraguay, Peru 
(2), Uruguay, Venezuela 
2002 11 82 87.8 
2003 13 83 75.9 
2004 15 88 79.5 
2006 13 84 84.5 
2007 15 107 88.8 
2008 17 120 71.7 
2009 21 150 77.3 
2010 22 132 80.0 
2011 23 144 83.7 
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Table 3 (continued).  
Region-based categorization of EQAS participants’ performance of Salmonella serotyping 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4. Salmonella serogroups (SG), serotypes (ST) and deviations (D), WHO EQAS 2011 
 
*number of participants reporting the specified deviating result 
 
Region EQAS iteration 
No. of 
labs 
No. of 
strains 
serotyped  
% strains 
correctly 
serotyped 
Countries participating 
 in EQAS 2011 
Southeast Asia  
2001 15 113 54.0 
Brunei Darussalam, Cambodia, 
Japan (2), Korea Rep. of (2),  
Lao P.´s Dem. Rep., Malaysia (3), 
Mexico, Philippines, Singapore,  
Sri Lanka, Taiwan, Thailand (8) 
 
2002 12 90 92.2 
2003 15 100 81.0 
2004 17 130 81.5 
2006 15 117 84.6 
2007 19 140 91.4 
2008 18 125 81.6 
2009 23 180 81.1 
2010 24 172 90.5 
2011 23 180 98.4 
Strain 
ID Correct serotype 
No. of labs 
reporting 
SG 
% DSG 
No. of labs 
reporting 
ST 
% 
DST 
Deviating results (*) 
WHO 
S-11.1 
Muenchen (or 
Virginia) 6,8:d:1,2 141 1.4 126 5.6 
Bsilla (2), Lindenburg (1), Manhattan (1), 
Newport (1), O:6,8 H: d,1,2][Z67] (1), 
Valdosta, (1) 
WHO 
S-11.2 Westhampton 3,10:g,s,t:- 137 5.8 126 9.5 
Senftenberg (5), Regent (2), Amsterdam 
(2) Lekke (1), London (1), groupe II (1) 
WHO 
S-11.3 Haifa 4,12:z10:1,2 144 2.8 124 9.7 
Saintpaul (3), Tokoin (2), Albert (1), 
Heidelberg (1), Huettwilen 
(1),Kisangani(1), Stanley (1), Tudu (1), 
Typhimurium (1) 
WHO 
S-11.4 Derby 4,12:f,g:- 138 0.7 125 14.4 
Agona(8), Hato (2), Salamae(II) (2), 
1,4,12,27:g,t:- (1), Agona II (1), 
Bredeney (1), Budapest (1), Salmonella 
(1), Stanley (1), 
WHO 
S-11.5 Havana 13,23:f,g:- 128 4.7 121 6.6 
Dublin (2), Raus (2), Agbeni (1), 
Newyork (1), Okatie (1), Viridi (1) 
WHO 
S-11.6 Onireke 3,10:d:1,7 137 3.6 123 8.9 
Birmingham (2), Lekke (2), Shangani (2), 
Give (1), London (1), Ontario (1), 
Stormont (1), Weybridge (1) 
WHO 
S-11.7 Enteritidis 9,12:g,m:- 141 1.4 130 1.5 
Berta (1), Salamae(II) (1) 
 
WHO 
S-11.8 Abaetetuba 11:k:1,5 127 3.9 119 10.1 
Pretoria (6), Harburg (1), Nyanza (1),  
Poona (1), Remete (1), Straengnaes (1), 
Salamae(II) (1) 
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Table 5. EQAS participating laboratories’ performance of internal quality control strain (WHO  
S-11.7, Salmonella Enteritidis) serotyping  
 
EQAS 
iteration 
Labs serotyping  
S. Enteritidis correctly 
No. % 
2000 34 92 
2001 64 84 
2004 113 95 
2006 116 94 
2007 135 96 
2008 139 96 
2009 141 93 
2010 138 97 
2011 128 98 
Average 112 95 
 
 
 
Table 6. EQAS participating laboratories’ performance of antimicrobial susceptibility testing of Salmonella strains 
 
EQAS 
iteration 
No. of EQAS 
participating 
laboratories  
% correct test 
results 
 
% minor deviations 
(S ↔ I or I ↔ R)^  
% major 
deviations 
(S → R)^ 
% very major 
deviations  
(R→ S)^ 
% critical deviations 
(R→ S & S → R)^ 
% total deviations 
(S → R & R → S & S ↔ 
I or I ↔ R)^ 
2000 44 92 4 4 0 4 8 
2001 108 91 6 2 1 3 9 
2002 119 92 6 2 1 3 9 
2003* 147 93 4 3 0 3 7 
2004 152 93 4 2 1 3 7 
2006 143 88 8 3 1 4 12 
2007 143 93 4 2 1 3 7 
2008 168 91 4 2 3 5 9 
2009 153 94 3 2 1 3 6 
2010 152 92 4 3 2 5 8 
2011 127 91 4 2 3 5 9 
Average* 132 92 5 2 1 4 8 
*Data do not include one strain which may have lost resistance due to transport or storage stress 
^S, susceptible; I, intermediate; R, resistant 
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Table 7. Antimicrobial susceptibility test results (number of R/I/S) for the EQAS 2011 Salmonella strains* 
 
^For antimicrobial abbreviations: see List of Abbreviations page 1 
*In bold: expected interpretation. Grey cell: <90% of laboratories did correct interpretation. R, resistant/I, intermediate/ S, susceptible. 
 
 
 
 
 
 
 
 
 
 
 
 
Strain Antimicrobial^ 
AMP CTX CAZ CRO CHL CIP GEN NAL STR SMX SXT TET TMP 
WHO 
S-11.1 7/1/130 4/2/108 3/0/101 4/0/89 1/0/125 2/0/131 3/0/123 1/1/122 83/0/4 67/0/1 3/0/121 126/0/1 2/0/62 
WHO 
S-11.2 7/3/128 6/2/106 3/1/100 3/0/90 2/0/122 6/0/128 4/1/119 0/10/115 2/5/78 4/1/62 2/0/121 2/4/122 1/0/60 
WHO 
S-11.3 5/4/128 5/0/109 3/2/98 2/1/89 1/0/123 74/3/56 6/1/118 123/1/1 7/22/55 67/0/1 121/0/3 126/0/2 61/0/0 
WHO 
S-11.4 137/0/1 6/4/103 8/2/93 5/2/87 2/1/121 59/2/73 5/0/119 6/27/91 5/22/57 3/2/63 4/0/120 126/0/2 1/0/61 
WHO 
S-11.5 132/0/6 110/1/4 99/1/5 87/0/7 116/0/7 4/0/131 108/2/15 2/1/122 77/2/8 63/1/4 112/1/10 59/40/28 59/0/3 
WHO 
S-11.6 136/0/1 5/0/109 2/0/102 0/0/93 1/0/122 77/7/51 4/0/121 58/32/33 1/17/66 2/2/64 2/0/121 1/2/124 0/0/62 
WHO 
S-11.7 19/3/115 6/3/104 4/1/98 1/0/92 1/3/119 13/0/121 125/0/1 3/3/118 80/1/7 67/0/1 2/0/122 8/5/115 0/1/59 
WHO 
S-11.8 6/1/129 2/1/109 0/1/102 1/0/91 0/0/121 4/0/128 4/0/120 1/3/119 3/16/64 3/3/61 1/0/122 0/4/120 0/0/61 
 26 
Table 8. EQAS participants’ performance of Salmonella strains antimicrobial susceptibility testing categorized by antimicrobial 
 
EQAS 
iteration 
No. of 
labs Performance 
Antimicrobial∞ 
AMC AMP CAZ CHL CIP POD CRO CTX GEN KAN NAL SMX STR SXT TET TMP XNL OVERALL 
2000 44 
No. of tests - 343 - 343 334 -     343 312 328 248 312 - 335 295 - 3,193 
% critical deviations* - 6 - 4 1 -     4 4 1 3 4 - 6 1 - 3 
% total deviations^ - 8 - 7 6 -     5 16 4 5 12 - 13 1 - 8 
2001 108 
No. of tests - 822 - 814 813 -     821 623 726 431 679 757 804 416 - 7,706 
% critical deviations*  - 4 - 2 1 -     2 2 2 6 7 2 7 1 - 3 
% total deviations^ - 7 - 3 4 -     4 7 8 9 27 5 18 2 - 9 
2002 119 
No. of tests - 918 - 903 911 -     905 680 885 495 718 724 861 499 - 8,499 
% critical deviations* - 2 - 2 0 -     2 2 2 4 4 7 3 3 - 3 
% total deviations^ - 3 - 3 2 -     16 10 4 4 34 10 7 3 - 9 
2003● 147 
No. of tests - 1,019 - 996 995 -     993 738 947 615 768 929 995 582 - 9,577 
% critical deviations* - 2 - 1 0 -     2 2 1 4 9 2 4 1 - 3 
% total deviations^ - 4 - 2 1 -     2 6 4 5 39 2 11 1 - 7 
2004 152 
No. of tests 973 1,178 - 1,159 1,162 - - 995 1,201 - 1,130 734 947 1051 1,122 729 - 12,381 
% critical deviations* 6 3 - 2 0 - - 0 2 - 1 5 1 3 5 2 - 3 
% total deviations^ 12 5 - 2 1 - - 14 3 - 4 8 21 4 11 2 - 7 
2006 143 
No. of tests 950 1,092 769 1,060 1,110 305 - 956 1,078 - 1,035 649 896 996 1,054 607 225 12,782 
% critical deviations* 9 2 7 3 2 1 - 7 3 - 2 6 5 3 9 1 2 4 
% total deviations^ 22 3 11 15 6 26 - 15 7 - 6 7 22 5 20 2 9 12 
2007 143 
No. of tests 908 1,114 830 1,105 1,101 389 - 914 1,111 - 1,092 678 875 971 1,047 583 258 12,976 
% critical deviations* 6 5 1 0 1 4 - 1 3 - 2 5 4 3 4 1 0 3 
% total deviations^ 17 7 1 6 1 16 - 2 4 - 3 6 26 3 11 2 6 7 
2008 168 
No. of tests - 1,331 961 1,226 1,307 - 791 1,104 1,265 - 1,168 718 867 1,155 1,249 696 - 13,858 
% critical deviations* - 3 3 1 19 - 3 3 4 - 2 4 7 3 6 2 - 5 
% total deviations^ - 8 6 11 21 - 6 6 6 - 4 5 25 4 13 2 - 9 
2009 153 
No. of tests - 1,206 921 1,108 1,190 - 775 1,009 1,143 - 1,095 624 864 1,042 1,114 616 - 12,707 
% critical deviations* - 3 1 1 8 - 0 1 2 - 1 7 9 3 4 1 - 3 
% total deviations^ - 6 1 2 10 - 1 2 3 - 3 9 30 4 10 1 - 6 
2010 152 
No. of tests - 1,173 937 1,118 1,194 - 787 1,026 1,133 - 1,096 566 800 1,012 1,134 604 - 12,580 
% critical deviations* - 4 2 1 3 - 4 4 5 - 1 14 19 4 5 1 - 5 
% total deviations^ - 5 3 2 3 - 8 8 6 - 2 17 55 4 9 1 - 9 
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Table 8 (continued). EQAS participants’ performance of Salmonella strains antimicrobial susceptibility testing categorized by antimicrobial. 
 
Legend Figure 8 
 
∞For antimicrobial abbreviations: see List of Abbreviations page 1 
*R→ S & S → R (R, resistant; S, susceptible) 
^S→R & R→S & S↔I or I↔R (I, intermediate) 
● Data do not include one strain which may have lost resistance due to transport or storage stress 
-, not determined 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
EQAS 
iteration 
No. of 
labs Performance 
Antimicrobial∞ 
AMC AMP CAZ CHL CIP POD CRO CTX GEN KAN NAL SMX STR SXT TET TMP XNL OVERALL 
2011 127 
No. of tests - 1099 829 988 1070 - 744 909 999 - 993 542 682 988 1017 493 - 11353 
% critical deviations* - 5 3 2 20 - 3 4 4 - 7 4 3 3 4 1 - 5 
% total deviations^ - 6 4 2 21 - 3 6 5 - 15 5 42 3 10 2 - 9 
Average● 133 
No. of tests 944 1027 875 984 1017 347 774 988 999 588 954 573 764 963 976 556 242 798 
% critical deviations* 7 4 3 2 5 3 3 3 3 3 2 6 7 3 5 1 1 4 
% total deviations^ 17 6 4 5 7 21 5 8 6 10 5 7 30 4 12 2 8 9 
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Table 9. Region-based categorization of EQAS participants’ performance of Salmonella antimicrobial susceptibility testing 
 
Region EQAS 
iteration 
No. 
of 
labs 
 
% correct 
test 
result 
 
% minor 
deviations  
(S ↔ I or 
I ↔ R)^ 
 
% major 
deviations 
(S → R)^ 
 
 
% very 
major 
deviations 
(R → S)^ 
 
% critical 
deviations 
(S → R & 
R → S)^ 
 
% total 
deviations 
(S→R & R→S 
& S↔I or 
I↔R)^ 
Countries participating 
in the 2011 iteration 
A
fr
ic
a 
2001 7 80.1 9.6 7.7 2.5 10.2 19.8 
Cameroon, Central 
African, Republic 
Congo, Rep. Of, Ivory 
Coast, Ghana, Kenya, 
Madagascar, Mauritius,  
Morocco (2), Nigeria 
(2), Seychelles, South 
Africa, Sudan, Tunisia, 
Zambia 
2002 10 94.3 4.1 1.0 0.6 1.6 5.7 
2003 13 86.9 6.6 2.8 3.7 6.5 13.1 
2004 11 85.7 7.2 5.2 1.9 7.1 14.3 
2006 20 85.8 7.5 4.1 2.7 6.8 14.3 
2007 16 90,7 4.4 4.0 0.9 4.9 9.3 
2008 19 83.8 6.5 5.5 4.2 9.7 16.2 
2009 22 90.1 4.5 3.6 1.8 5.4 9.9 
2010 22 84.7 6.0 6.5 2.8 9.3 15.3 
2011 17 87.0 5.0 4.7 3.3 8.0 13.0 
C
en
tr
al
 A
sia
 &
 M
id
dl
e 
Ea
st
  2001 10 87.7 6.3 5.2 0.8 6.0 12.3 
Iran Islamic Republic 
of, Israel, Jordan, 
Oman 
 
2002 6 83.4 9.8 6.6 0.2 6.8 16.6 
2003 8 89.9 4.5 4.0 1.6 5.6 10.1 
2004 10 87.5 6.7 5.5 0.3 5.8 12.5 
2006 7 79.2 10.5 9.8 0.5 10.3 20.8 
2007 8 87.8 5.0 6.2 1.1 7.3 12.2 
2008 12 86.1 6.5 4.0 3.4 7.4 13.9 
2009 6 93.7 4.3 0.9 1.1 2.0 6.3 
2010 7 95.8 2.6 0.2 1.4 1.6 4.2 
2011 4 91.8 4.1 1.8 2.3 4.1 8.2 
C
ar
ib
be
an
  
2001 2 83.5 9.5 7.0 0.0 7.0 16.5 
Barbados, Jamaica 
 
2002 1 95.8 4.2 0.0 0.0 0.0 4.2 
2003 8 91.7 6.4 1.5 0.5 2.0 8.4 
2004 8 94.1 3.1 1.9 0.9 2.8 5.9 
2006 5 92.1 5.4 1.6 1.0 2.6 8.0 
2007 4 95.0 3.1 0.9 0.9 1.8 5.0 
2008 5 90.7 5.5 0.9 2.9 3.8 9.3 
2009 4 93.2 1.8 3.2 1.8 5.0 6.8 
2010 4 90.9 5.4 2.7 0.7 3.4 8.8 
2011 2 96.5 1.4 0.0 2.1 2.1 3.5 
Eu
ro
pe
 
2001 47 91.3 5.7 2.7 0.3 3.0 8.7 Albania, Belgium,  
Bosnia and Herzegovina 
(2), Bulgaria (2), 
Croatia, Denmark (2), 
Estonia, Finland, 
France, Greece (2), 
Hungary, Ireland, Italy 
(9), Lithuania, 
Luxembourg, Malta, 
Poland (3), Serbia,  
Slovakia, Slovenia, 
Turkey, United 
Kingdom 
2002 57 92.7 5.2 1.2 0.9 2.1 7.3 
2003 64 92.9 3.8 1.0 2.3 3.3 7.1 
2004 58 93.5 4.3 1.4 0.8 2.2 6.5 
2006 54 88.7 7.0 3.8 0.6 4.4 11.3 
2007 49 94.2 3.7 1.6 0.4 2.0 5.7 
2008 51 91.2 4.4 2.5 1.9 4.4 8.8 
2009 40 95.1 2.6 1.3 0.9 2.2 4.8 
2010 39 92.4 4.1 1.2 2.3 3.5 7.6 
2011 36 92.5 4.5 1.7 1.3 3.0 7.5 
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Table 9 (continued). Region-based categorization of EQAS participants’ performance of Salmonella antimicrobial susceptibility testing 
Region EQAS 
iteration 
No. 
of 
labs 
 
% correct 
test result 
 
 
 
% minor 
deviations  
(S ↔ I or 
I ↔ R)^ 
 
% major 
deviations 
(S → R)^ 
 
% very 
major 
deviations 
(R → S)^ 
 
% critical 
deviations 
(S → R & 
R → S)^ 
 
% total 
deviations 
(S→R & R→S 
& S↔I or 
I↔R)^ 
Countries participating 
in the 2011 iteration 
N
or
th
 A
m
er
ic
a 
 
2001 4 95.8 3.8 0.0 0.4 0.4 4.2 
Canada (5), United States 
of America (4) 
2002 3 90.5 6.9 0.6 2.0 2.6 9.5 
2003 7 93.4 5.2 0.0 1.4 1.4 6.6 
2004 9 94.2 4,2 1.8 0.0 1.8 6.0 
2006 8 94.8 2.9 1.0 1.3 2.3 5.2 
2007 10 95.4 2.9 0.8 0.8 1.6 4.6 
2008 14 96.4 0.6 0.4 2.6 3.0 3.6 
2009 10 98.7 0.0 0.4 0.9 1.3 1.3 
2010 11 94.8 2.6 0.2 2.4 2.6 5.2 
2011 9 92.1 2.6 1.5 3.8 5.3 7.9 
O
ce
an
ia
  
2001 6 91.8 4.7 2.7 0.9 3.6 8.2 
Australia (3), New Zealand 
 
2002 7 91.7 6.2 0.0 2.0 2.0 8.3 
2003 9 94.3 2.5 1.2 2.0 3.2 5.7 
2004 11 97.1 2.5 0.3 0.1 0.4 2.9 
2006 7 93.4 4.6 0.9 1.1 2.0 6.6 
2007 1 98.9 1.1 0.0 0.0 0.0 1.1 
2008 4 93.9 3.8 0.0 2.3 2.3 6.1 
2009 4 95.9 3.2 0.3 0.6 0.9 4.1 
2010 4 92.5 4.6 0.6 2.3 2.9 7.5 
2011 4 93.8 5.6 0.6 0.0 0.6 6.2 
R
us
si
a 
 
2001 1 81,9 15,3 2,8 0.0 2.8 18.1 
Belarus, Georgia, Russian 
Federation (5) 
 
2002 1 84,5 9,9 5,6 0.0 5.6 15.5 
2003 1 100.0 0.0 0.0 0.0 0.0 0.0 
2004 4 91.2 6.6 1.5 0.7 2.2 8.8 
2006 5 87.4 8.2 2.7 1.7 4.4 12.6 
2007 8 88.9 5.8 4.8 0.4 5.2 11.0 
2008 6 92.2 4.7 1.4 1.7 3.1 7.8 
2009 6 93.8 2.1 3.3 0.8 4.1 6.2 
2010 8 94.3 3.3 1.3 1.1 2.4 5.7 
2011 7 90.0 4.8 3.2 2.0 5.2 10.0 
La
tin
 A
m
er
ic
a 
 
2001 11 90.8 6.9 1.4 1.0 2.4 9.2 
Argentina, Belize, Brazil 
(2), Chile, Colombia (2), 
Costa Rica, Cuba, Ecuador 
(2), Guatemala (2), 
Honduras, Mexico,  
Nicaragua, Panama, 
Paraguay, Peru, 
Suriname, Uruguay, 
Venezuela 
2002 13 93.7 4.6 0.7 1.0 1.7 6.3 
2003 12 90.8 4.2 2.0 3.0 5.0 9.2 
2004 17 94.4 4.7 0.8 0.1 0.9 5.6 
2006 16 88.7 6.3 4.5 0.6 5.1 11.3 
2007 17 94.9 1.8 1.9 1.4 3.3 5.0 
2008 20 93.0 3.4 1.5 2.1 3.6 7.0 
2009 20 95.6 2.1 1.1 1.2 2.3 4.4 
2010 23 90.8 2.1 5.6 1.4 7.1 9.2 
2011 22 90,8 2,8 3,1 3,3 6.4 9,2 
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Table 9 (continued). Region-based categorization of EQAS participants’ performance of Salmonella antimicrobial susceptibility testing. 
Region EQAS 
iteration 
No. 
of 
labs 
 
% correct 
test result 
 
 
 
% minor 
deviations  
(S ↔ I or 
I ↔ R)^ 
 
% major 
deviations 
(S → R)^ 
 
% very 
major 
deviations 
(R → S)^ 
 
% critical 
deviations 
(S → R & 
R → S)^ 
 
% total 
deviations 
(S→R & R→S 
& S↔I or 
I↔R)^ 
Countries participating 
in the 2011 iteration 
So
ut
he
as
t A
sia
  
2001 16 88.1 7.7 2.3 1.9 4.2 11.9 
 
 
Brunei Darussalam, 
Cambodia, India (5), 
Japan (2), Korea Rep. Of 
(2), Lao P.´s Dem. Rep., 
Malaysia (4), Nepal, 
Philippines, Sri Lanka (2), 
Taiwan, Thailand (4), Viet 
Nam 
2002 18 89.0 8.1 1.4 1.6 3.0 11.0 
2003 17 87.4 5.2 4.7 2.7 7.4 12.6 
2004 16 92.8 4.4 2.3 0.5 2.8 7.2 
2006 15 90.0 8.1 1.2 0.8 2.0 10.0 
2007 20 93.9 4.0 1.4 0.7 2.1 6.1 
2008 19 90.5 4.7 2.2 2.6 4.8 9.5 
2009 27 91.8 4.1 3.0 1.2 4.2 8.3 
2010 25 92.8 3.8 1.5 1.9 3.4 7.2 
 2011 26 90.5 3.5 2.4 3.5 5.9 9.5 
^S, susceptible; I, intermediate; R, resistant 
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Table 10. EQAS participants’ performance of antimicrobial susceptibility testing of quality control strain Escherichia coli ATCC 25922 
 
Method Labs' 
perfor-
mance5,6 AMC AMP CAZ CHL CIP POD CRO CTX ENR
2 FFN2 FIS (SMX)3 GEN NAL STR SXT TET TMP XNL
2 
Accepted 
interval1 
MIC (μg/ml)    2-8 2-8 0.06-0.5 2-8 0.004-0.016 
0.25-
1 
0.03-
0.12 
0.03-
0.12 
0.008-
0.03 2-8 8-32 0.25-1 1-4 4-16
4 ≤0.5/9.5 0.5-2 0.5-2 0.25-1 
Disks (mm)   18-24 16-22 25-32 21-27 30-40 23-28 29-35 29-35 32-40 22-28 15-23 19-26 22-28 12-20 23-29 18-25 21-28 26-31 
EQ
A
S 
ite
ra
tio
n 
(to
ta
l n
o.
 o
f p
ar
tic
ip
an
ts
) 
2000 
(44) 
MIC & Disk No.
5 - 37 - 38 35 - - - - - 19 39 37 36 - 42 31 - 
%6 - 27 - 37 20 - - - - - 53 23 35 22 - 42 30 - 
2001 
(107) 
MIC & Disk No.
5 - 97 - 97 97 - - - - - 53 99 74 81 90 96 50 - 
%6 - 19 - 20 14 - - - - - 34 12 14 12 14 22 22 - 
2002 
(114) 
MIC & Disk No.
5 - 109 - 107 108 - - - - - 57 108 102 82 102 102 66 - 
%6 - 16 - 15 14 - - - - - 26 12 14 11 12 13 11 - 
2003 
(144) 
MIC & Disk No.
5 - 140 - 137 138 - - - - - 82 138 132 105 129 137 79 - 
%6 - 14 - 22 9 - - - - - 17 9 16 9 14 19 14 - 
2004 
(140) 
MIC & Disk No.
5 117 132 - 128 132 - - 111 - - 84 134 126 110 120 129 87 - 
%6 13 10 - 13 8 - - 18 - - 16 10 9 6 11 13 9 - 
2006 
(137) 
MIC & Disk No.
5 116 133 96 126 127 39 - 115 19 - 74 131 122 106 122 125 74 32 
%6 9 14 15 18 8 12 - 21 63 - 29 14 20 11 19 12 17 22 
2007 
(126) 
MIC & Disk No.
5 102 124 92 123 121 47 - 104 - 13 64 124 120 97 107 117 67 35 
%6 8 11 9 14 12 9 - 16 - 0 22 6 7 6 13 7 10 11 
2008 
(147) 
MIC & Disk No.
5 - 147 111 135 144 - - 124 - - 71 145 136 101 129 139 79 - 
%6 - 12 9 10 8 - - 14 - - 14 8 8 12 13 7 13 - 
MIC No.
5 - 33 23 24 33 - - 23 - - 18 31 23 19 22 28 16 - 
%6 - 0 5 0 6 - - 9 - - 11 0 0 11 9 0 13 - 
Disk No.
5 - 114 89 112 111 - - 101 - - 53 114 113 82 107 111 63 - 
%6 - 16 10 12 8 - - 15 - - 15 11 10 12 14 9 13 - 
2009 
(129) 
MIC & Disk No.
5 - 128 100 121 124 - 88 107 - - 63 123 117 98 113 122 70 - 
%6 - 16 13 15 7 - 16 10 - - 11 18 13 10 14 14 11 - 
MIC No.
5 - 27 19 24 26 - 20 20 - - 14 25 24 19 21 27 25 - 
%6 - 11 11 8 8 - 15 15 - - 21 12 8 5 19 11 13 - 
Disk No.
5 - 101 81 97 98 - 68 87 - - 49 98 93 79 92 95 55 - 
%6 - 16 14 16 6 - 16 9 - - 10 18 14 11 12 15 11 - 
2010 
(116) 
MIC & Disk No.
5 - 114 97 108 115 - 79 100 - - 51 112 104 84 101 110 63 - 
%6 - 11 9 9 6 - 10 14 - - 11 11 5 5 12 5 15 - 
MIC No.
5 - 25 15 21 25 - 15 17 - - 12 24 19 17 17 24 11 - 
%6 - 12 20 10 8 - 7 18 - - 8 13 16 18 18 17 36 - 
Disk No.
5 - 89 82 87 90 - 64 83 - - 39 88 85 67 84 86 52 - 
%6 - 9 6 8 4 - 9 11 - - 10 9 2 1 10 1 8 - 
2011 
(111) 
MIC & Disk No.
5 - 111 89 102 109 - 76 96 - - 50 103 103 72 99 107 51 - 
%6 - 17 4 11 7 - 7 9 - - 8 11 8 4 16 7 14 - 
MIC No.
5 - 23 15 18 22 - 16 15 - - 13 22 19 17 16 21 11 - 
%6 - 4 7 0 9 - 6 0 - - 8 9 0 6 6 5 0 - 
Disk No.
5 - 88 74 84 87 - 60 81 - - 37 81 84 55 83 86 40 - 
%6 - 20 4 13 7 - 7 11 - - 8 11 10 4 18 8 18 - 
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Legend table 10 
0For antimicrobial abbreviations: see List of Abbreviations page 1 
1CLSI standard, Performance Standards for Antimicrobial Disk and Dilution Susceptibility testing. 21th Informational supplement. CLSI document M100-S21, Wayne, Pennsylvania 
2CLSI standard, Performance Standards for Antimicrobial Disk and Dilution Susceptibility Tests for bacteria Isolated from Animals. M31-A3. 3rd Edition[Approved Standard]. 2008. 
Wayne, PA, USA 
3FIS (sulfisoxazole) covers the group of SMX (sulfonamides) 
4Quality control range developed by the manufacturer of Sensititre 
5No., number of labs performing the analysis 
6%, percentage of labs reporting erroneous results 
-, not determined 
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Table 11. Shigella serotypes (ST) and deviations (D), WHO EQAS 2011 
*number of participants reporting deviating result  
 
 
 
 
 
 
 
 
 
Strain Correct 
serotype 
 
No. of labs 
reporting 
correct 
identification 
D (%) Deviating 
results (*) 
No. of labs 
reporting 
correct ST 
D (%) Deviating 
results (*) 
WHO 
SH-11.1 
S. flexneri  
serotype 6 104 2.8 3 66 5,7 
4a (2), 3 (1),  
1b (1) 
WHO 
SH-11.2 S. sonnei 105 2.8 3 N/A N/A N/A 
WHO 
SH-11.3 
S. boydii 
 serotype 2 102 1.9 2 48 5,9 
1 (1), 11 (1),  
14 (1) 
WHO 
SH-11.4 
S. flexneri 
serotype 1b 109 0.9 1 53 11,7 
1a (6), 3a  
(1) 
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Table 12. Region-based categorization of laboratories performing Shigella serotyping in 2011 
 
Region Year No. of 
laboratories 
No. of strains 
serotyped 
Strains serotyped 
correctly (%) 
Countries participating in the 2011 iteration 
Africa 
2009 8 18 72.2 
Kenya, Mauritius, South Africa, Tunisia 2010 7 16 62.5 
2011 4 10 100.0 
Central Asia & 
Middle East  
2009 3 5 100.0 
Israel, Oman 2010 3 6 83.3 
2011 2 6 100.0 
Europe  
2009 15 40 92.5 Albania, Belgium, Bosnia and Herzegovina, Bulgaria, Czech Republic, 
Denmark, Finland, Germany, Greece, Ireland, Italy, Lithuania, Luxembourg,  
Malta, Serbia, Slovenia, Turkey, United Kingdom 
2010 15 35 85.7 
2011 16 42 92.9 
North America  
2009 7 18 100.0 
Canada (4), United States of America (2) 2010 7 20 100.0 
2011 6 16 100.0 
Oceanic  
2009 3 8 100.0 
Australia, New Zealand 2010 3 8 100.0 
2011 3 8 100.0 
Russia  
2009 6 18 83.3 
Belarus, Georgia, Russian Federation (4) 2010 7 20 75.0 
2011 6 18 88.9 
Latin America  
2009 16 40 97.5 
Argentina, Brazil (2), Chile, Colombia, Costa Rica, Cuba, Ecuador, Mexico, 
Nicaragua, Panama, Paraguay, Peru, Uruguay, Venezuela 2010 13 33 78.8 
2011 15 37 94.6 
Southeast Asia  
2009 11 30 90.0 Japan (2), Korea Rep. of, Lao P.´s Dem. Rep., Malaysia, Seychelles, Sri 
Lanka, Taiwan, Thailand (5) 
 
2010 14 32 87.5 
2011 13 33 84.8 
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Table 13. EQAS participating laboratories’ performance of Shigella strains antimicrobial susceptibility testing  
 
EQAS iteration No. of 
participating 
laboratories 
% correct test 
results 
% minor 
deviations 
(S ↔ I or I ↔ R)^ 
% major 
deviations 
(S → R)^ 
% very major 
deviations 
(R → S)^ 
% critical 
deviations 
(S → R & R → S )^ 
% total 
deviations 
(S → R & R → S & 
S ↔ I or I ↔ R)^ 
2008 15 95 2 2 1 3 5 
2009 111 96 2 1 1 2 4 
2010 114 91 2 1 6 7 9 
2011 107 92 2 1 4 5 7 
^S, susceptible; I, intermediate; R, resistant 
 
 
Table 14. Antimicrobial susceptibility test results (number of R/I/S) for the EQAS 2011 Shigella strains* 
 
Strain Antimicrobial∞ 
AMP CTX CAZ CRO CHL CIP GEN NAL STR SMX SXT TET TMP 
WHO SH-11.1 9/4/86 2/0/83 1/0/78 0/0/69 1/0/85 3/0/95 2/0/87 1/1/89 2/17/40 0/0/46 2/0/88 2/2/87 2/0/43 
WHO SH-11.2 98/0/1 83/0/1 64/9/7 71/0/1 3/0/86 40/1/56 4/0/84 87/1/3 58/0/3 42/0/1 88/0/2 89/0/3 44/0/0 
WHO SH-11.3 11/5/86 3/0/84 2/0/80 1/0/72 0/0/89 49/2/50 4/2/86 88/3/3 62/0/1 44/0/1 90/0/5 4/1/91 43/0/2 
WHO SH-11.4 102/0/1 84/0/3 61/13/7 71/0/4 78/7/4 51/4/45 2/2/86 8/21/64 60/0/3 44/0/1 93/03 96/0/1 44/0/0 
∞For antimicrobial abbreviations: see List of Abbreviations page 1 
*In bold: expected interpretation. Grey cell: <90% of laboratories did correct interpretation. R, resistant; I, intermediate; S, susceptible. 
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Table 15. EQAS laboratories’ performance of Shigella strains antimicrobial susceptibility testing categorized by antimicrobial 
 
EQAS 
iteration 
No. of 
labs 
Lab 
performance 
Antimicrobial 
AMP CAZ CHL CIP CTX GEN NAL SMX STR SXT TET TMP CRO OVERALL 
2008 15 
No. of tests 52 44 51 48 48 50 52 7 27 52 52 4 42 529 
% critical deviations* 1 2 1 - 2 1 - - 4 2 4 - 2 1.5 
% total deviations^ 1 2 1 - 2 1 - - 9 2 8 - 2 2.2 
2009 111 
No. of tests 423 358 388 426 372 396 388 211 293 388 386 218 301 4548 
% critical deviations* 2.4 0.3 2.1 0.2 1.1 2.5 0.5 3.8 5.8 2.3 2.8 1.8 0.3 1.9 
% total deviations^ 3.8 0.3 4.6 0.9 1.1 3.5 1.5 3.8 18.1 3.6 7.5 1.8 0.6 3.8 
2010 114 
No. of tests 424 344 402 434 377 403 382 194 275 363 410 218 291 4517 
% critical deviations* 1.7 0.6 3.5 40.8 2.4 3.5 2.1 4.6 8.0 8.3 4.4 3.7 0.0 6.4 
% total deviations^ 1.9 1.2 9.2 77.9 3.0 5.5 3.0 6.0 14.6 13.8 5.9 3.8 0.0 11.2 
2011 107 
No. of tests 403 322 353 396 343 359 369 179 246 371 376 178 289  
% critical deviations* 5.5 5.2 2.2 38.9 2.7 3.3 4.0 1.7 3.6 3.2 2.7 2.2 2.0 5.5 
% total deviations^ 7.7 12.0 4.2 40.7 2.7 4.4 11.0 1.7 10.5 3.2 3.5 2.2 2.0 7.7 
∞For antimicrobial abbreviations: see List of Abbreviations page 1 
*R→ S & S → R (R, resistant; S, susceptible) 
^S→R & R→S & S↔I or I↔R (I, intermediate) 
-, not determined
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Table 16. Region-based categorization of EQAS participating laboratories’ performance of antimicrobial susceptibility tests for Shigella strains in 2011  
 
Region Year No. of 
labs 
 
% correct 
test result 
% minor 
deviations 
(S↔I or I↔R)^ 
% major 
deviations 
(S→R)^ 
% very major 
deviations 
(R→ S)^ 
% critical 
deviations 
(R→ S & S → R)^ 
% total 
deviations 
(S→R & R→S & 
S↔I or I↔R)^ 
Countries participating in the 2011 
iteration 
Africa 
2009 17 93.3 2.4 3.5 0.8 4.3 6.8 Cameroon, Central African Republic, Congo, 
Rep. of, Ivory Coast, Ghana, Kenya, Madagascar, 
Mauritius, Morocco, Nigeria (2), Seychelles, 
South Africa, Sudan, Tunisia,Zambia 
2010 16 84.8 2.5 2.7 10.0 12.7 15.2 
2011 16 86.0 1.8 3.6 8.3 11.9 13.7 
Central Asia 
& Middle 
East  
2009 5 94.8 0.9 3.0 1.3 4.4 5.2 
Jordan, Iran, Israel, Oman 2010 6 90.6 1.2 1.6 6.7 8,3 9.4 
2011 4 92.9 1.6 0.5 4.9 5.4 7.1 
Caribbean  
2009 4 95.6 1.5 0.7 2.2 2.9 4.4 
Barbados 
 2010 4 88.5 1.5 3.8 6.2 10.0 11.5 
2011 1 97.7 2.3 0.0 0.0 2,3 2.3 
Europe  
2009 22 98.1 1.1 0.7 0.1 0.8 1.9 Albania, Belgium, Bosnia and Herzegovina (2), 
Bulgaria, Denmark (2), Finland, Greece, Ireland, 
Italy (5), Lithuania, Luxembourg, Malta, Poland 
(2), Serbia, Slovenia, Turkey, United Kingdom 
2010 27 93.6 1.5 0.9 3.9 4.8 6.4 
2011 24 94.8 2.2 0.5 2.5 3.0 5.1 
North 
America  
2009 6 100.0 0.0 0.0 0.0 0.0 0.0 
Canada, United States of America 2010 7 95.0 0.0 0.0 5.0 5.0 5.0 
2011 4 90.1 0.7 3.3 5.9 9,2 9.9 
Oceanic  
2009 - - - - - - - 
Australia 2010 1 90.0 10.0 0.0 0.0 0.0 10.0 
2011 1 92.5 5.0 0.0 2.5 2.5 7.5 
Russia  
2009 6 95.5 1.6 1.6 1.3 2.9 4.6 
Belarus, Georgia, Russian Federation 
 2010 7 92.1 2.9 1.5 3.5 5.0 7.9 
2011 6 94.4 3.6 0.0 2.0 2.0 5.6 
Latin 
America  
2009 20 98.3 1.1 0.4 0.3 0.7 1.7 Argentina, Belize, Brazil (2), Chile, Colombia, 
Costa Rica, Ecuador (2), Guatemala (2), 
Honduras, Mexico, Nicaragua, Panama, Paraguay, 
Peru, Suriname, Uruguay, Venezuela 
2010 22 92.1 1.3 2.1 4.5 6.6 7.9 
2011 20 94.0 1.5 1.3 3.2 4.5 6.0 
Southeast 
Asia  
2009 18 94.1 3.9 0.3 1.7 2.0 5.9 Cambodia, India (5), Japan (2), Korea Rep. Of, 
Lao P.´s Dem. Rep., Malaysia (2), Nepal, 
Philippines, Sri Lanka (2), Thailand (3) 
2010 16 90.5 2.4 0.7 6.4 7.1 9.5 
2011 19 90.0 2.1 0.8 6.1 6.9 9.0 
^S, susceptible; I, intermediate; R, resistant. 
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Table 17. Proportion of laboratories that obtained the expected result. Number (n/N) and percentages of 
laboratories which correctly detected and confirmed the ESBL and non ESBL producing Salmonella and 
Shigella strains. 
 
Isolate no. Expected interpretation Confirmatory tests 
CAZ/CL:CAZ CTX/CL:CTX 
WHO S-11.1 non ESBL 17/17 (100%) 22/22 (100%) 
WHO S-11.2 non ESBL 18/19 (95%) 22/24 (92%) 
WHO S-11.3 non ESBL 17/18 (94%) 22/22 (100%) 
WHO S-11.4 non ESBL 18/19 (95%) 22/23 (96%) 
WHO S-11.5 ESBL 53/56 (95%) 58/63 (95%) 
WHO S-11.6 non ESBL 17/17 (100%) 23/23 (100%) 
WHO S-11.7 non ESBL 19/19 (100%) 23/23 (100%) 
WHO S-11.8 non ESBL 16/17 (94%) 21/21 (100%) 
WHO SH-11.1 non ESBL 12/12 (100%) 17/17 (100%) 
WHO SH-11.2 ESBL 42/44 (95%) 46/50 (92%) 
WHO SH-11.3 non ESBL 12/13 (92%) 17/17 (100%) 
WHO SH-11.4 ESBL 42/43 (98%) 45/49 (92%) 
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Table 18. EQAS participating laboratories’ performance of Campylobacter strains identification 
 
EQAS 
iteration 
No. of 
labs 
Correct species Strain no. No. of 
results 
submitted 
% correct 
identification 
Deviating results (*) 
2003 
97 C. jejuni # 1 92 87%  C. coli (9) C. lari (3) 
97 C. coli # 2 92 83%  
C. jejuni (7) 
C. lari (4) 
C. upsaliensis (4) 
2004 
109 C. lari # 1 95 80%  C. coli (11) C. jejuni (8) 
109 C. jejuni # 2 107 87%  
C. coli (8) 
C. lari (4) 
C. upsaliensis (2) 
2006 
99 C. jejuni # 1 86  90% 
C. lari (3) 
C. coli (3) 
C. upsaliensis (3) 
99 C. coli # 2 94  66%  
C. lari (19) 
C. jejuni (11) 
C. upsaliensis (2) 
2007 
142 C. lari # 1 95  72% 
C. jejuni (10) 
C. coli (9) 
C. upsaliensis (7) 
142 C. coli # 2 99  74%  
C. lari (3) 
C. jejuni (20) 
C. upsaliensis (2) 
2008 
154 C. lari # 1 105 63% 
C. coli (14) 
C. jejuni (18) 
C. upsaliensis (7) 
154 C. lari # 2 105 60% 
C. coli (10) 
C. jejuni (19) 
C. upsaliensis (13) 
2009 
131 C. coli # 1 87 77% 
C. upsaliensis (10) 
C. jejuni (9) 
C. lari (1) 
131 C. jejuni # 2 87 95% C. upsaliensis (3) C. lari (1) 
2010 
130 C. jejuni # 1 88 92% 
C. coli (4)  
C. lari (3) 
C. upsaliensis (1) 
130 C. coli # 2 84 85% 
C. jejuni (11)  
C. lari (2)  
C. upsaliensis (2) 
2011 
132 C. coli # 1 81 59% 
C. jejuni (19)  
C. lari (13)  
C. upsaliensis (1) 
132 C. coli # 2 79 70% 
C. jejuni (17)  
C. lari (5)  
C. upsaliensis (2) 
*number of participants reporting the specified deviating result 
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Table 19. Region-based categorization of EQAS 2011 participating laboratories’ performance of Campylobacter strains identification 
Region Year No. of labs 
No. of strains 
identified 
% strains 
correctly 
identified 
Countries participating in the 2011 iteration 
Africa 
2009 8 13 54 
Cameroon, Central African Republic, Ivory Coast, Kenya, Madagascar, Mauritius, 
South Africa, Sudan, Tunisia 2010 7 13 77 
2011 9 17 35 
Central Asia & 
Middle East 
2009 3 5 40 
Israel, Oman, Saudi Arabia 2010 3 6 100 
2011 2 2 50 
Caribbean 
2009 2 4 100 
Barbados 2010 3 6 67 
2011 1 2 0 
Europe 
2009 28 53 89 Bulgaria, Cyprus, Czech Republic, Denmark (2), Estonia, Finland, Germany, 
Greece, Hungary, Italy (8), Lithuania, Luxembourg. Malta, Poland (2), Serbia, 
Turkey 
2010 29 57 96 
2011 25 48 85 
North America 
2009 10 19 90 
Canada, United States of America 2010 11 22 86 
2011 9 18 78 
Oceania 
2009 2 4 100 
Australia, New Zealand 2010 2 3 100 
2011 2 4 100 
Russia 
2009 2 4 100 
Belarus, Georgia 2010 2 4 100 
2011 2 4 50 
Latin America 
2009 14 26 89 
Argentina (2), Brazil (2), Chile, Colombia (3), Costa Rica, Ecuador, Guatemala (2), 
Mexico, Paraguay, Peru (2), Uruguay, Venezuela (2)  2010 19 37 78 
2011 19 37 49 
Southeast Asia 
2009 10 20 90 
Brunei Darussalam, Cambodia, India, Japan, Korea Rep. Of, Lao P.´s Dem. Rep., 
Malaysia, Philippines, Taiwan, Thailand (3) 2010 14 27 93 
2011 12 24 67 
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Table 20. EQAS participants’ performance of Campylobacter strains antimicrobial susceptibility 
testing 
 
EQAS 
iteration 
No. of 
labs  
% correct 
test results 
 
% major 
deviations 
(S → R)^ 
% very major 
deviations 
(R → S)^ 
% critical 
deviations 
(R → S & S → R)^ 
2009 25 91.4 4.5 4.1 8.6 
2010 37 91.3 4,2 4,5 8,7 
2011 32 93,8 2,8 3,4 6.2 
^S, susceptible; R, resistant 
 
 
Table 21. Antimicrobial susceptibility test results (number of R/S) for the EQAS 2011 
Campylobacter strains* 
 
 
 
 
 
 
 
 
 
^For antimicrobial abbreviations, see List of Abbreviations page 1 
*In bold: expected interpretation. R, resistant; S, susceptible 
 
 
Table 22. EQAS participants’ performance of Campylobacter antimicrobial susceptibility testing 
categorized by antimicrobial 
 
EQAS 
iteration 
No. of 
labs 
Lab 
performance 
Antimicrobial 
CHL CIP ERY GEN NAL STR TET 
2009 
 
25 
 
No. of tests 37 46 46 43 41 34 45 
% critical deviations* 8.1 6.5 10.8 2.3 9.8 11.8 11.1 
2010 
 
37 
No. of tests 44 70 71 59 53 39 68 
% critical deviations* 4.8 7.7 12.7 11.3 8.2 11.4 9.7 
2011 
 
32 
No. of tests 41 67 62 65 62 30 60 
% critical deviations* 0.0 6.0 6.5 3.1 8.1 13.3 8.3 
^For antimicrobial abbreviations, see List of Abbreviations page 1 
*R→ S & S → R (R, resistant; S, susceptible)
Strain 
Antimicrobial^ 
CHL CIP ERY GEN NAL STR TET 
WHO 
C-11.1 0/21 32/2 1/30 1/31 28/3 14/1 1/29 
WHO 
C-11.2 0/20 2/31 28/3 1/32 2/29 3/12 26/4 
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Table 23. Region-based categorization of EQAS 2011 participants’ performance of antimicrobial susceptibility testing of Campylobacter strains 
 
Region Year No. of 
labs 
% correct 
test result 
% major 
deviations 
(S → R)^ 
% very major 
deviations 
(S → R)^ 
% critical 
deviations 
(R→S & S→R)^ 
Countries participating in the 2011 iteration 
 
 
Africa 
2009 2 50.0 21.4 28.6 50.0 
Cameroon, Central African Republic, Ivory Coast, 
Madagascar, Sudan, Tunisia 2010 2 95.2 0.0 4.8 4.8 
2011 6 82.7 3.8 13.5 17.3 
Central Asia & Middle East 
2009 0 - - - - 
Iran 2010 0 - - - - 
2011 1 75.0 0.0 25.0 25.0 
Europe 
2009 9 98.3 1.7 0.0 1.7 
Denmark (2), Greece, Hungary, Italy (3), Luxembourg, 
Malta, Poland (2) 2010 13 100.0 0.0 0.0 0.0 
2011 11 100.0 0.0 0.0 0.0 
North America 
2009 2 100.0 0.0 0.0 0.0 
Canada, United States of America. 2010 5 93.8 6.3 0.0 6.3 
2011 5 100.0 0.0 0.0 0.0 
Oceanic 
2009 0 - - - - 
Australia 2010 0 - - - - 
2011 1 100.0 0.0 0.0 0.0 
Russia 
2009 0 - - - - 
Georgia 2010 1 78.6 7.1 14.3 21.4 
2011 1 100.0 0.0 0.0 0.0 
Latin America 
2009 5 93.2 6.8 0.0 6.8 
Argentina, Brazil, Chile, Costa Rica, Paraguay,Peru (2) 2010 8 89.6 6.0 4.5 10.4 
2011 7 96.8 0.0 3.2 3.2 
Southeast Asia 
2009 4 71.4 0.0 28.6 28.6 
Japan, Korea Rep. Of, Philippines, Thailand (2) 2010 7 77.2 9.8 13.0 22.8 
2011 5 85.1 9.0 6.0 15.0 
^S, susceptible; R, resistant 
 
 45 
Table 24. EQAS 2011 participants’ performance of antimicrobial susceptibility testing of 
Campylobacter jejuni ATCC 33560 
 
 
Method used Incubation conditions 
Labs’ 
performance1, 2 
Antimicrobial3 
CHL CIP ERY GEN NAL TET 
EQAS 
2010 
(N=20) 
Microdilution 42°C / 24h 
No.1 3 6 6 6 4 6 
%2 67 83 100 83 75 83 
Microdilution 36-37°C / 48h 
No.1 5 8 8 8 7 8 
%2 80 88 88 75 86 88 
Agardilution 42°C / 24h 
No.1 0 6 6 6 0 0 
%2 0 100 83 83 0 0 
Agardilution 36-37°C / 48h 
No.1 0 0 0 0 0 0 
%2 0 0 0 0 0 0 
Overall Overall 
No.1 8 20 20 20 11 14 
%2 75 90 90 80 82 86 
EQAS 
2011 
(N=26) 
Microdilution 42°C / 24h 
No.1 4 9 9 8 7 9 
%2 100 67 100 88 100 67 
Microdilution 36-37°C / 48h 
No.1 6 8 6 8 7 7 
%2 83 88 100 75 86 86 
Agardilution 42°C / 24h 
No.1 - 8 8 8 - - 
%2 - 88 63 100 - - 
Agardilution 36-37°C / 48h 
No.1 - 1 1 1 - - 
%2 - 0 0 100 - - 
Overall Overall 
No.1 10 26 24 25 14 16 
%2 90 77 83 88 93 75 
1No., number of labs performing the analysis 
2%, percentage of labs reporting correct results 
3For antimicrobial abbreviations: see List of Abbreviations page 1 
-, not determined 
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Table 25. EQAS participating laboratories’ performance of unknown strain identification  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
EQAS 
iteration 
Strain ID No. of 
participating labs 
Pecentage (%) of labs 
performing correct 
identification  
2003 E. coli O157 115 99 
2004 Shigella flexneri 121 94 (Shigella) 74 (S. flexneri) 
2006 Yersinia enterocolitica O3 134 
93 (Yersinia) 
89 (Y. enterocolitica) 
66 (Y. enterocolitica O3) 
2007 Vibrio parahaemolyticus 86 83  
2008 Enterobacter sakasakii 128 92  
2009 Vibrio mimicus 56 48  
2010 Citrobacter spp. 115 90 
2011 Aeromonas hydrophila 106 83 
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Appendixes (1, 2, 3, 4a, 4b) 
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DFVF- M00-06-001/21.05.2010 
Lyngby, 14 April 2011 
SIGN-UP FOR EQAS 2011 
Greetings to the WHO Global Foodborne Infections Network (WHO GFN) Members: 
WHO GFN strives to increase the quality of laboratory-based surveillance of Salmonella and other 
foodborne pathogens by encouraging national and regional reference laboratories that attended 
WHO GFN training courses to participate in the External Quality Assurance System (EQAS). The 
2010 EQAS cycle is completed, and we are pleased to announce the launch of the 2011 EQAS 
cycle. 
 
EQAS provides the opportunity for proficiency testing which is considered an important tool for the 
production of reliable laboratory results of consistently good quality. 
WHY PARTICIPATE IN EQAS? 
 
This year, WHO EQAS offers the following components:  
WHAT IS OFFERED IN EQAS? 
- serogrouping, serotyping and antimicrobial susceptibility testing of eight Salmonella isolates;  
- serotyping and antimicrobial susceptibility testing of four Shigella isolates;  
- species identification and antimicrobial susceptibility testing of two Campylobacter isolates;  
- identification of one unknown bacterial isolate. 
 
All national and regional reference laboratories which perform analysis on Salmonella, Shigella 
and/or Campylobacter and are interested in performing quality assurance are invited to participate. 
WHO SHOULD PARTICIPATE IN EQAS 2011? 
We expect that all national and regional reference laboratories that attended WHO GFN Training 
Courses will participate in EQAS.  
The WHO GFN Regional Centers in cooperation with the EQAS Coordinator will evaluate the list 
of laboratories that sign-up for EQAS 2011. Laboratories which signed-up and received bacterial 
isolates in year 2010 but did not submit any result should provide a consistent explanation if they 
want to participate in 2011.  
 
There is no participation fee in EQAS 2011. However, laboratories should cover the expenses for 
parcel shipment if they can afford it. If your country has an agreement with FedEx regarding import 
of Biological Substance Category B (UN3373), please provide your FedEx import account number 
in the sign-up form or, alternatively, to the EQAS Coordinator (please find contact information 
below). We need this information at this stage to save time and resources. Participating laboratories 
are responsible for paying any expenses related to taxes or custom fees applied by their country.  
COST FOR PARTICIPATING IN EQAS 
 
 
 
 
   Appendix 1, page 2 of 2 
This link will open a sign-up webpage: 
HOW TO SIGN- UP FOR EQAS 2011 
http://thor.dfvf.dk/signup 
In this webpage, you will be asked to provide the following information: 
-       Name of institute, department, laboratory and contact person 
-       Complete mailing address for shipment of bacterial isolates (no post-office box number) 
-       Telephone and fax number, E-mail address 
-       FedEx import account number (if available) 
-       Approximate number of Salmonella isolates annually serogrouped/serotyped 
-       Approximate number of Salmonella isolates annually tested for antimicrobial susceptibility 
-       Availability of ATCC reference strains 
-       Components of EQAS 2011you plan to perform (level of participation) 
-       Level of reference function in your country  
 
If you experience any problem in the sign-up webpage, please try again a few days later. If 
problems persist after several attempts, please contact the EQAS Coordinator Susanne Karlsmose: 
E-mail suska@food.dtu.dk; fax +45 3588 6341.  
 
Due to increased number of participants in WHO EQAS, a number of different institutions will ship 
the bacterial isolates, and you will receive information concerning the institution shipping your 
parcel. The bacterial isolates will be shipped between August and September 2011. 
TIMELINE FOR SHIPMENT OF ISOLATES AND AVAILABILITY OF PROTOCOLS 
In order to minimize delays, please send a valid import permission to the EQAS coordinator. 
Please apply for a permit to receive the following (according to your level of participation): 
“Biological Substance Category B”: eight Salmonella strains, four Shigella strains, two 
Campylobacter, one Campylobacter reference strain (for new participants performing antimicrobial 
susceptibility testing on Campylobacter), one Escherichia coli reference strain (for new participants 
performing antimicrobial susceptibility testing on Salmonella and/or Shigella) and an unknown 
sample (enteric bacteria) between August and September 2011. 
 
Protocols and all relevant information will be available for download from the website 
http://www.antimicrobialresistance.dk/233-169-215-eqas.htm. 
 
Results must be submitted to the National Food Institute (DTU Food) by 31
DEADLINE FOR SUBMITTING RESULTS TO THE NATIONAL FOOD INSTITUTE 
st
Deadline for sign-up for EQAS 2011 is 
 December 2011 
through the password-protected website. An evaluation report will be generated upon submission of 
results. Full anonymity is ensured, and only DTU Food and the WHO GFN Regional Centre in your 
region will have access to your results. 
30th May 2011 
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WHO 2011 S-11.1 Salmonella Muenchen  6,8:d:1,2 <= 1 SUSC = 0.25 SUSC = 0.5 SUSC = 0.125 SUSC = 4 SUSC = 0.03 SUSC = 1 SUSC <= 4 SUSC > 128 RES > 1024 RES > 32 RES <= 1 SUSC = 0.125 SUSC
WHO 2011 S-11.2 Salmonella  Westhampton  3,10:g,s,t:- <= 1 SUSC <= 0.12 SUSC = 0.5 SUSC = 0.09 SUSC = 8 SUSC = 0.06 SUSC <= 0.5 SUSC = 8 SUSC <= 8 SUSC <= 64 SUSC <= 2 SUSC <= 1 SUSC = 0.09 SUSC
WHO 2011 S-11.3 Salmonella Haifa  4,12:z10:1,2 = 2 SUSC <= 0.12 SUSC = 1 SUSC <= 0.25 SUSC = 8 SUSC = 0.5 RES = 2 SUSC > 64 RES = 16 INTERM > 1024 RES > 32 RES > 32 RES > 32 RES
WHO 2011 S-11.4 Salmonella Derby  4,12:f,g:- > 32 RES <= 0.12 SUSC = 1 SUSC = 0.064 SUSC = 4 SUSC = 0.5 RES <= 0.5 SUSC = 8 SUSC = 16 INTERM <= 64 SUSC > 32 RES <= 1 SUSC = 0.125 SUSC
WHO 2011 S-11.5 Salmonella Havana  13,23:f,g:- > 32 RES > 4 RES = 32 RES > 256 RES > 64 RES = 0.03 SUSC > 16 RES <= 4 SUSC > 128 RES > 1024 RES = 16 RES > 32 RES > 32 RES ESBL-producer; bla (CTX-M15)
WHO 2011 S-11.6 Salmonella Onireke  3,10:d:1,7 > 32 RES = 0.25 SUSC = 0.38 SUSC <= 0.25 SUSC = 4 SUSC = 1 RES = 1 SUSC = 16 SUSC = 16 INTERM <= 64 SUSC <= 2 SUSC <= 1 SUSC = 0.125 SUSC
WHO 2011 S-11.7 Salmonella Enteritidis  9,12:g,m:- = 4 SUSC = 0.5 SUSC = 1 SUSC = 0.25 SUSC = 8 SUSC = 0.06 SUSC > 16 RES <= 4 SUSC = 128 RES > 1024 RES = 4 SUSC <= 1 SUSC = 0.064 SUSC
WHO 2011 S-11.8 Salmonella Abaetetuba  11:k:1,5 <= 1 SUSC <= 0.12 SUSC = 0.25 SUSC = 0.064 SUSC = 8 SUSC = 0.03 SUSC = 1 SUSC <= 4 SUSC = 16 INTERM <= 64 SUSC <= 2 SUSC <= 1 SUSC = 0.064 SUSC
WHO 2011 SH-11.1 Shigella flexneri  type 6 = 4 SUSC <= 0.125 SUSC = 0.25 SUSC = 0.032 SUSC =  4 SUSC <= 0.015 SUSC = 1 SUSC = 4 SUSC = 16 SUSC <= 64 SUSC <= 2 SUSC <= 1 SUSC = 0.64 SUSC
WHO 2011 SH-11.2 Shigella sonnei > 32 RES > 4 RES = 4 RES > 256 RES =  4 SUSC = 0.25 RES = 2 SUSC = 64 RES > 128 RES > 1024 RES > 32 RES > 32 RES > 32 RES ESBL-producer; 
bla (CMY-2)
WHO 2011 SH-11.3 Shigella boydii  type 2 = 2 SUSC <= 0.125 SUSC = 0.25 SUSC = 0.032 SUSC <= 2 SUSC = 0.25 RES = 2 SUSC = 64 RES > 128 RES > 1024 RES <= 2 SUSC > 32 RES > 32 RES
WHO 2011 SH-11.4 Shigella flexneri type 1b > 32 RES > 4 RES = 4 RES > 256 RES > 64 RES = 1 RES = 2 SUSC = 8 SUSC >  128 RES > 1024 RES > 32 RES > 32 RES > 32 RES ESBL-producer; bla(CTX-M15)
WHO 2011 C-11.1 C. coli = 4 SUSC > 4 RES <= 0.5 SUSC = 0.25 SUSC = 64 RES > 16 RES <= 0.25 SUSC
WHO 2011 C-11.2 C. coli = 4 SUSC = 0.5 SUSC > 32 RES = 0.25 SUSC = 8 SUSC <= 1 SUSC > 16 RES
WHO B-11.1 Aeromonas hydrophila
TMP SXT
Trim/SulfaTrimethoprimAmpicillin Cefotaxime Ceftazidime Ceftriaxone Chloramphenicol
CIP GEN NAL STRAMP CTX CAZ
STR TET
Chloramphenicol Ciprofloxacin
Ciprofloxacin Gentamicin
CHL CIP ERY GEN NAL
CRO CHL
Nalidixic acid Streptomycin Sulfonamides Tetracycline
Erythromycin Gentamicin Nalidixic acid Streptomycin Tetracycline
SMX TET
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1 INTRODUCTION 
In 2000, the Global Foodborne Infections Network (formerly known as WHO Global Salm-Surv) 
launched an External Quality Assurance System (EQAS). The EQAS is organized by the National 
Food Institute, Technical University of Denmark (DTU Food), in collaboration with partners and 
Regional Sites in WHO GFN.  
Various aspects of the proficiency test scheme may be subcontracted from time to time. When 
subcontracting occurs, it is placed with a competent subcontractor and the National Food Institute is 
responsible for the subcontractor’s work. 
The WHO EQAS 2011 includes:  
- serotyping and antimicrobial susceptibility testing of eight Salmonella strains,  
- serotyping and antimicrobial susceptibility testing of four Shigella strains,  
- antimicrobial susceptibility testing of the Escherichia coli ATCC 25922 (CCM 3954), 
reference strain for quality control,  
- identification and antimicrobial susceptibility testing of two thermophilic Campylobacter 
isolates,  
- antimicrobial susceptibility testing of Campylobacter jejuni ATCC 33560 (CCM 6214), 
reference strain for quality control,  
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- identification of one ‘unknown’ bacterial isolate.  
All participants will receive the strains according to the information they reported in the sign-up 
form.  
The above mentioned reference strains are included in the parcel only for new participants of the 
EQAS who did not receive them previously. The reference strains are original CERTIFIED cultures 
provided free of charge, and should be used for future internal quality control for antimicrobial 
susceptibility testing in your laboratory. The reference strains will not be included in the years to 
come. Therefore, please take proper care of these strains. Handle and maintain them as suggested in 
the manual ‘Subculture and Maintenance of QC Strains’ available on the WHO CC website (please 
see www.antimicrobialresistance.dk). 
2 OBJECTIVES 
The main objective of this EQAS is to support laboratories to assess and, if necessary, improve the 
quality of serotyping and antimicrobial susceptibility testing of enteric human pathogens, especially 
Salmonella. A further objective is to assess and improve the comparability of surveillance data on 
Salmonella serotypes and antimicrobial susceptibility reported by different laboratories. Therefore, 
the laboratory work for this EQAS should be done by using the methods routinely used in your 
laboratory. 
3 OUTLINE OF THE EQAS 2011 
3.1 Shipping, receipt and storage of strains 
In August/September 2011, some 180 laboratories located worldwide will receive a parcel 
containing eight Salmonella strains, four Shigella strains, two Campylobacter strains and one 
‘unknown’ bacterial isolate (according to information reported in the sign-up form). An E. coli 
ATCC 25922 reference strain and a C. jejuni ATCC 33560 reference strain will be included for 
participants who signed up to perform antimicrobial susceptibility testing (AST) and did not receive 
them previously. All provided strains are non-toxin-producing human pathogens Class II. ESBL-
producing strains could be included in the selected material.  
 Please confirm receipt of the parcel through the confirmation form enclosed in the shipment.  
The Salmonella and Shigella strains and the ‘unknown’ bacterial isolate are shipped as agar stab 
cultures, whereas the reference strains and the Campylobacter strains are shipped lyophilized. On 
arrival, the agar stab cultures must be subcultured and prepared for storage in your strain collection 
(e.g. in a -80 °C freezer). This set of cultures should serve as reference if discrepancies are detected 
during tests (e.g. they can be used if errors such as mis-labelling or contamination occur). 
Lyophilized strains must be reconstituted, and you can find below a suggested procedure. 
3.2 Serotyping of Salmonella  
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The eight Salmonella strains should be serotyped by using the method routinely used in the 
laboratory. If you do not have all the necessary antisera, please go as far as you can in the 
identification and report the serogroup since also serogroup results will be evaluated. Serogroups 
should be reported by using terms according to Kauffmann-White-Le Minor (Grimont and Weill, 
2007. 9th ed. Antigenic formulae of the Salmonella serovars. WHO Collaborating Centre for 
Reference and Research on Salmonella). 
Please fill-in information concerning the brand of antisera used for typing in the fields available in 
the database for entering results. In addition, we kindly ask you to report which antisera you think is 
required to complete the serotyping, if relevant.  
3.3 Antimicrobial susceptibility testing of Salmonella, Shigella and E. coli ATCC 25922  
The Salmonella and Shigella strains and the E. coli ATCC 25922 reference strain should be tested 
for susceptibility towards as many as possible of the antimicrobials mentioned in the test form. 
Please use the methods routinely used in your laboratory.  
For reconstitution of the E. coli reference strain, please see the document ‘Instructions for opening 
and reviving lyophilized cultures’ on the WHO CC website (please find the link at 
www.antimicrobialresistance.dk). 
Testing of gentamicin and streptomycin susceptibility may be valuable for monitoring purposes. 
Therefore, we kindly ask you to disregard, for the purpose of this proficiency testing, that the 
Clinical and Laboratory Standards Institute (CLSI) guidelines state that Salmonella and Shigella 
should not be reported as susceptible to aminoglycosides. 
The breakpoints used in this EQAS for interpreting MIC results are in accordance with CLSI 
values, and are supplemented with values from the European Committee on Antimicrobial 
Susceptibility Testing (EUCAST, www.eucast.org) and DTU Food (Table 1). Consequently, 
interpretation of MIC results will lead to categorization of strains into three categories: resistant (R), 
intermediate (I) and susceptible (S). In the evaluation report that you receive upon result 
submission, you can find that obtained interpretations in accordance with the expected 
interpretation will be defined as ‘correct’, whereas deviations from the expected interpretation will 
be defined as ‘minor’ (I ↔ S or I ↔ R), ‘major’ (S interpreted as R) or ‘very major’ (R interpreted 
as S).  
Please report the breakpoints that you routinely use in your laboratory for interpretation of 
antimicrobial susceptibility test results in the fields available in the database (or in the test forms). 
Concerning ciprofloxacin susceptibility test, please note that a low breakpoint has been used to 
determine the resistance category. This low breakpoint corresponds to the EUCAST 
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epidemiological cut-off value, which was established to take into consideration mechanisms of 
resistance like qnr genes or one point-mutation in the gyrase gene (Table 1; www.eucast.org).  
In this EQAS, microorganisms showing reduced susceptibility to ciprofloxacin are considered 
ciprofloxacin-resistant. 
Table 1. Interpretive breakpoint for Salmonella and Shigella antimicrobial susceptibility testing 
Antimicrobials  Reference value, MIC (µg/mL) Reference value, Disk diffusion (mm) 
Sensitive Intermediate Resistant Sensitive Intermediate Resistant 
Ampicillin, AMP ≤8 16 ≥32 ≥17 14-16 ≤13 
Cefotaxime, CTX ≤1 - >1 >27 - ≤27 
Ceftazidime, CAZ ≤1 - >1 >22 - ≤22 
Ceftriaxone, CRO ≤1 - >1 >25 - ≤25 
Chloramphenicol, CHL ≤8 16 ≥32 ≥18 13-17 ≤12 
Ciprofloxacin, CIP <0.125* - ≥0.125* 
≥23mm 
(1µg)*** 
or 
≥30mm 
(5µg)*** 
- 
<23mm 
(1µg)*** 
or 
<30mm 
(5µg)*** 
Gentamicin, GEN ≤4 8 ≥16 ≥15 13-14 ≤12 
Nalidixic acid, NAL ≤16 - ≥32 ≥19 14-18 ≤13 
Streptomycin, STR ≤8** 16** ≥32** ≥15 12-14 ≤11 
Sulfonamides, SMX
 
  
≤256 - ≥512 ≥17 13-16 ≤12 
Tetracycline, TET ≤4 8 ≥16 ≥15 12-14 ≤11 
Trimethoprim, TMP ≤8 - ≥16 ≥16 11-15 ≤10 
Trimethoprim + 
sulfamethoxazole, 
TMP+SMX, SXT 
≤2/38 - ≥4/76 ≥16 11-15 ≤10 
Reference values used in this EQAS are according to CLSI, with the following exceptions:         
* EUCAST (epidemiological cut-off values)      
** DTU Food 
*** In the absence of values provided by EUCAST, the article by Cavaco LM and Aarestrup FM (J. Clin. 
Microbiol. 2009. Sep;47(9):2751-8) provides the background for these interpretative criteria in the WHO 
GFN EQAS. In that article, Shigella was not included. However, the same interpretative criteria will be used 
in this context. 
Important notes: beta-lactam resistance 
The following tests for detection of Extended-Spectrum Beta-Lactamase (ESBL) production are 
optional: 
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All strains showing reduced susceptibility to cefotaxime (CTX), ceftazidime (CAZ) and/or 
ceftriaxone (CRO) could be tested for ESBL production by confirmatory test. 
Confirmatory test for ESBL production requires use of both cefotaxime (CTX) and ceftazidime 
(CAZ) alone and in combination with a β-lactamase inhibitor (clavulanic acid). Synergy is defined 
either as i) a ≥ 3 twofold concentration decrease in an MIC for either antimicrobial agent tested in 
combination with clavulanic acid vs. its MIC when tested alone (E-test 3 dilution steps difference; 
MIC CTX : CTX/CL or CAZ : CAZ/CL ratio ≥ 8) or ii) a ≥ 5 mm increase in a zone diameter for 
either antimicrobial agent tested in combination with clavulanic acid vs. its zone when tested alone 
(CLSI M100 Table 2A; Enterobacteriaceae). The presence of synergy indicates ESBL production. 
 
Of note, MIC values and relative interpretation of cefotaxime (CTX), ceftazidime (CAZ) and/or 
ceftriaxone (CRO) used for detection of beta-lactamase-producing strains in this EQAS should be 
reported as found, which is in accordance with EUCAST expert rules. 
 
3.4 Handling the Campylobacter strains 
Freeze-dried cultures are supplied in vacuum-sealed ampoules. Care should be taken in opening the 
ampoule, and all instructions given below should be followed closely to ensure the safety of the 
person who opens the ampoule and to prevent contamination of the culture. 
a. Check the number of the culture written on the label. 
b. Make a file cut on the ampoule just above the shoulder of the ampoule. 
c. Disinfect the ampoule with alcohol-dampened gauze or alcohol-dampened cotton wool. 
d. Crack the glass using sterile gauze or cotton to protect your fingers. 
e. Add to the dried suspension about 0.5 ml of appropriate broth or sterile 0.9% NaCl solution 
by using a pipette. Mix carefully to avoid creating aerosols.  
f. Inoculate the suspension on a suitable agar plate with a 10 µl loop or a cotton swab.  
g. Transfer the rest of the content of the ampoule to a test tube containing 5-6 ml of a suitable 
liquid media. 
h. Incubate the agar plate and liquid media at a temperature of 42°C at microaerobic conditions 
for 24-48 hours. 
i. Inoculate a second agar plate from the liquid media with a 10 µl loop or a cotton swab if the 
initial plate had inadequate growth. 
j. Select a pure culture with vigorous growth from the agar plate for further work. 
 
Please note that:  
• Cultures may need at least one subculture before they can be optimally used  
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• Unopened ampoules should be kept in a dark and cool place! 
For reconstitution of C. jejuni ATCC 33560 reference strain: please see the document ‘Instructions 
for opening and reviving lyophilised cultures’ on the WHO CC website (please find the link at 
www.antimicrobialresistance.dk). 
3.5 Identification of Campylobacter  
The two thermophilic Campylobacter isolates should be identified to the species level.  
3.6 Antimicrobial susceptibility testing of Campylobacter and C. jejuni ATCC 33560 
The Campylobacter test strains and the C. jejuni reference strain should be tested for susceptibility 
to as many antimicrobials as possible among the ones mentioned in the test form. Please note that 
only MIC methods (i.e. broth or agar dilution methods) are recommendable for AST of 
Campylobacter. Neither the use of disk diffusion nor E-test is recommendable for AST of 
Campylobacter.  
In this EQAS, the breakpoints used for interpretation of MIC results for Campylobacter are 
epidemiological cut-off values according to EUCAST (www.eucast.org; Table 2). Consequently, 
only two categories of characterization (resistant, R and sensitive, S) are allowed. In the evaluation 
report that you receive upon result submission, you can find that obtained interpretations that are in 
agreement with the expected interpretation will be categorized as ‘correct’, whereas deviations from 
the expected interpretation will be categorized as ‘incorrect’.  
Please report the breakpoints that you routinely use in your laboratory for interpretation of 
antimicrobial susceptibility test results in the fields available in the database (or in the test forms). 
Please note that the interpretation of antimicrobial susceptibility test results for Campylobacter 
requires knowledge of the Campylobacter species. If you did not sign up for Campylobacter 
identification but you perform AST on Campylobacter, you are welcome to contact the EQAS 
Coordinator to obtain information regarding the identity of the Campylobacter test strains. 
Appendix 3, page 6 of 10
WHO Collaborating Centre  
External Quality Assurance System (EQAS) 2011 
 
 
 
 
 
Page 7 of 10 
DFVF- M00-06-001/21.05.2010 – corrected 06.10.2011 
 
Table 2. Interpretive criteria for Campylobacter antimicrobial susceptibility testing 
Antimicrobials for Campylobacter C. jejuni C. coli 
 MIC (µg/mL) R is > 
MIC (µg/mL) 
R is > 
Chloramphenicol, CHL 16 16 
Ciprofloxacin, CIP 1 1 
Erythromycin, ERY 4 16 
Gentamicin, GEN 1 2 
Nalicixic acid, NAL 16 32 
Streptomycin, STR 2 4 
Tetracycline, TET 2 2 
Reference values for interpretation of Campylobacter AST results according to EUCAST 
 
The sub-cultured Campylobacter strains should be used for MIC testing after incubation at 36-37ºC 
for 48 hours or at 42ºC for 24 hours. Likely, two subcultures are needed prior to MIC testing to 
ensure optimal growth.  
3.7 Identification of the unknown environmental bacterium 
The ‘unknown’ isolate should be identified to the species level and further typed if relevant.  
4 REPORTING OF RESULTS AND EVALUATION 
Please write your results in the enclosed test forms, and enter your results into the interactive web 
database. 
We recommend reading carefully the description reported in paragraph 5 before entering your 
results in the web database. For entering your results via the web, you will be guided through all 
steps on the screen and you will immediately be able to view and print a report evaluating your 
results. Results in agreement with the expected interpretation are categorized as ‘correct’, while 
results deviating from the expected interpretation are categorized as ‘incorrect’. 
 
Results must be submitted no later than 31 December 2011. 
 
If you do not have access to the Internet, or if you experience difficulties in entering your results, 
please return the completed test forms by e-mail, fax or mail to the National Food Institute, 
Denmark. 
 
All results will be summarized in a report available to all participants. Individual results will be 
anonymous and will only be forwarded to the official GFN Regional Centre in your region.  
 
We are looking forward to receiving your results! 
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If you have any questions or concerns, please do not hesitate to contact the EQAS 
Coordinator: 
 
Susanne Karlsmose 
National Food Institute, Technical University of Denmark 
Kemitorvet, Building 204 ground floor, DK-2800 Lyngby - DENMARK 
Tel: +45 3588 6601, Fax: +45 3588 6341 
E-mail: suska@food.dtu.dk 
Please note that it is also possible to communicate with the EQAS organizers in languages different 
from English. However, this is not a direct contact with the EQAS organizers since translation of 
the message is required. The following languages may be used: Chinese, French, Portuguese, 
Russian and Spanish. 
 
5 HOW TO ENTER RESULTS IN THE INTERACTIVE DATABASE 
Please read these instruictions before entering the web page. Remember that you need by your side 
the completed test forms and the breakpoint values you used.  
In general, you navigate in the database with the Tab-key and mouse and, at any time, a click on the 
WHO logo takes you back to the main menu. 
1) Enter the WHO CC website (link available at http://www.antimicrobialresistance.dk), then 
a. Click on ‘EQAS’ 
b. Click on the link for the interactive database 
c. Write your username and password in lower-case letters and click on ‘Login’. 
You can find your username and password in the letter accompanying your parcel.  
Your username and password will remain unchanged in future trials. 
2) Click on ‘Materials and methods’  
a. Fill-in the fields relative to brand of antisera (very important because we would like to 
compare results obtained with different brands of antisera) 
b. Fill-in the fields relative to the method used for antimicrobial susceptibility testing 
c. Enter the brand of materials, e.g. Oxoid 
d. Fill-in the field asking whether your institute serves as a national reference laboratory 
e. In the comment field, report which antisera you think is required to complete your 
serotyping, if relevant 
f. Click on ‘Save and go to next page’ – REMEMBER TO SAVE EACH PAGE BEFORE 
LEAVING IT! 
3) In the data entry page ‘Routinely used breakpoints’ 
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a. Fill-in the fields relative to the breakpoints used routinely in your laboratory to determine 
the antimicrobial susceptibility category. Remember to use the operator keys in order to 
show: equal to (=), less than (<), less or equal to (≤), greater than (>) or greater than or 
equal to (≥). 
b. In the data entry pages ‘Salmonella strains 1-8’ 
c. SELECT the serogroup (O-group) from the drop-down list, DO NOT WRITE – Wait a few 
seconds – the page will automatically reload, so that the drop-down list in the field 
“Serotype” only contains serotypes belonging to the chosen serogroup.  
d. SELECT the serotype from the drop-down list – DO NOT WRITE – wait a few seconds 
and you can enter the antigenic formula (e.g. 1,4,5,12:i:1,2)  
e. Enter the zone diameters in mm or MIC values in µg/ml. Remember to use the operator 
keys to show e.g. equal to (=), etc… 
f. Enter the interpretation as R (resistant), I (intermediate) or S (susceptible) 
g. If you performed confirmatory tests for ESBL production, please choose the appropriate 
result from the pick list. 
h. If relevant, fill-in the field related to comments (e.g. which antisera you miss for complete 
serotyping, etc…) 
i. Click on ‘Save and go to next page’ 
If you did not perform these tests, please leave the fields empty  
4) In the data entry page ‘E. coli reference strain’: 
a. Enter the zone diameters in mm or MIC values in µg/ml. Remember to use the operator 
keys to show e.g. equal to (=), etc… 
b. Click on ‘Save and go to next page’ 
5) In the page ‘Identification of Campylobacter and unknown sample’:  
a. Choose the correct Campylobacter species from the pick list 
b. Fill-in the field concerning species and type of the unknown bacterial isolate, and report 
the method used for identification 
c. Click on ‘Save and go to next page’ 
If you did not perform these tests, please leave the fields empty 
6) The next page is a menu that allows you to review the input pages and approve your input and 
finally see and print the evaluated results 
a. Browse through the input pages and make corrections if necessary. Remember to click on 
‘save and go to next page’ if you make any corrections. 
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b. Approve your input. Be sure that you have filled-in all the results before approval, as 
.YOU CAN ONLY APPROVE ONCE!. The approval blocks your data entry into the 
interactive database, but allows you to see the evaluated results. 
c. As soon as you have approved your input, an evaluation report will appear.  
7) After browsing all pages in the report, you will find a new menu. You can choose ‘EQAS 2011 
start page’, ‘Review evaluated results’ (a printer friendly version of the evaluation report is also 
available) or ‘Go to Global Salm-Surv homepage’.   
End of entering your data – thank you very much! 
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SUBCULTURE AND MAINTENANCE OF    
QUALITY CONTROL STRAINS 
1.1 Purpose 
Improper storage and repeated subculturing of bacteria can produce alterations in antimicrobial 
susceptibility test results. The Clinical and Laboratory Standards Institute (CLSI, formerly NCCLS) 
has published a guideline for Quality Control (QC) stock culture maintenance to ensure consistent 
antimicrobial susceptibility test results. 
1.2 References 
M100-S21, January 2011 (Performance Standards for Antimicrobial Susceptibility Testing) 
M7-A8, January 2009 (Methods for Dilution Antimicrobial Susceptibility Test for Bacteria That 
Grow Aerobically; Approved Standard) 
1.3 Definition of Terms 
Reference Culture: A reference culture is a microorganism preparation that is acquired from a 
culture type collection.  
Reference Stock Culture: A reference stock culture is a microorganism preparation that is derived 
from a reference culture. Guidelines and standards outline how reference stock cultures must be 
processed and stored.  
Working Stock Cultures: A working stock culture is growth derived from a reference stock culture. 
Guidelines and standards outline how working stock cultures must be processed and how often they 
can be subcultured.  
Subcultures (Passages): A subculture is simply the transfer of established microorganism growth on 
media to fresh media. The subsequent growth on the fresh media constitutes a subculture or 
passage. Growing a reference culture or reference stock culture from its preserved status (frozen or 
lyophilized) is not a subculture. The preserved microorganism is not in a stage of established 
growth until it is thawed or hydrated and grown for the first time 
1.4 Important Considerations 
 Do not use disc diffusion strains for MIC determination. 
 Obtain QC strains from a reliable source such as ATCC 
 CLSI requires that QC be performed either on the same day or weekly (only after 30 day QC 
validation) 
 Any changes in materials or procedure must be validated with QC before implemented 
 For example: Agar and broth methods may give different QC ranges for drugs such as 
glycopeptides, aminoglycosides and macrolides 
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 Periodically perform colony counts to check the inoculum preparation procedure 
 Ideally, test values should be in the middle of the acceptable range 
 Graphing QC data points over time can help identify changes in data helpful for 
troubleshooting problems 
1.5 Storage of Reference Strains 
Preparation of stock cultures 
 Use a suitable stabilizer such as 50% fetal calf serum in broth, 10-15% glycerol in tryptic 
soy broth, defibrinated sheep blood or skim milk to prepare multiple aliquots. 
 Store at -20°C, -70°C or liquid nitrogen. (Alternatively, freeze dry.) 
 Before using rejuvenated strains for QC, subculture to check for purity and viability. 
Working cultures 
 Set up on agar slants with appropriate medium, store at 4-8°C and subculture weekly. 
 Replace the working strain with a stock culture at least monthly. 
 If a change in the organisms inherent susceptibility occurs, obtain a fresh stock culture or a 
new strain from a reference culture collection e.g. ATCC. 
1.6 Frequency of Testing 
Weekly vs. daily testing  
Weekly testing is possible if the lab can demonstrate satisfactory performance with daily testing as 
follows: 
 Documentation showing reference strain results from 30 consecutive test days were within 
the acceptable range. 
 For each antimicrobial/organism combination, no more than 3 out of 30 MIC values may be 
outside the acceptable range. 
When the above are fulfilled, each quality control strain may be tested once a week and whenever 
any reagent component is changed. 
Corrective Actions  
If an MIC is outside the range in weekly testing, corrective action is required as follows: 
 Repeat the test if there is an obvious error e.g. wrong strain or incubation conditions used 
 If there is no obvious error, return to daily control testing 
The problem is considered resolved only after the reference strain is tested for 5 consecutive days 
and each drug/organism result is within specification on each day. 
If the problem cannot be resolved, continue daily testing until the errors are identified. 
Repeat the 30 days validation before resuming weekly testing. 
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LYOPHILISED CULTURES 
 
 
Manual from  Czech Collection of Microorganisms (CCM) 
 Masaryk University 
 Tvrdého 14 
 602 00 BRNO 
 Czech Republic 
 
Lyophilised cultures are supplied in vacuum-sealed ampoules. Care should be taken in opening the 
ampoule. All instructions given below should be followed closely to ensure the safety of the person 
who opens the ampoule and to prevent contamination of the culture. 
a. Check the number of the culture on the label inside the ampoule 
b. Make a file cut on the ampoule near the middle of the plug 
c. Disinfect the ampoule with alcohol-dampened gauze or alcohol-dampened cotton wool from 
just below the plug to the pointed end 
d. Apply a red-hot glass rod to the file cut to crack the glass and allow air to enter slowly into 
the ampoule 
e. Remove the pointed end of the ampoule into disinfectant 
f. Add about 0.3 ml appropriate broth to the dried suspension using a sterile Pasteur pipette 
and mix carefully to avoid creating aerosols. Transfer the contents to one or more suitable 
solid and /or liquid media 
g. Incubate the inoculated medium at appropriate conditions for several days 
h. Autoclave or disinfect effectively the used Pasteur pipette, the plug and all the remains of 
the original ampoule before discarding 
Please note that:  
 Cultures should be grown on media and under conditions as recommended in the CCM 
catalogue 
 Cultures may need at least one subculturing before they can be optimally used in experiments 
 Unopened ampoules should be kept in a dark and cool place! 
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